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Iyer, Lavanya K. PhD, Purdue University, December 2015. High-Resolution Mass Spectrometric 
Approaches to Study Protein Structure and Environment in Lyophilized Solids. Major Professor: 
Elizabeth Topp. 
Proteins comprise a growing class of therapeutics that is used to treat various diseases such as 
diabetes and cancer. However, intrinsic structural features such as the primary sequence and 
extrinsic factors such as pH, temperature, agitation and metal ions can promote instability that 
manifests as chemical degradation (e.g. oxidation, deamidation, hydrolysis) and/or physical 
degradation (aggregation, phase separation). Since several degradation pathways are accelerated 
by diffusion in solution, proteins are lyophilized to improve stability. The lyophilized formulation may 
still undergo degradation during manufacture and/or storage. The mechanism of protein 
aggregation in lyophilized solids is not well understood or predictable by conventional analytical 
methods such as solid-state Fourier-transform infrared spectroscopy (ssFTIR) and differential 
scanning calorimetry (DSC) and this poses challenges in rational formulation design.  
 
This dissertation is aimed at understanding local protein structure and environment in the solid 
state using high-resolution mass spectrometric methods. Chapter 2 examines protein side-chain 
matrix accessibility using solid-state photolytic labeling- mass spectrometry (ssPL-MS). The use of 
a photoactive probe, photo-leucine (pLeu) enabled side-chain labeling in lyophilized formulations, 
reported by our group for the first time. High-resolution information at the peptide level was obtained 
using bottom-up tandem mass spectrometry. Differences in labeling patterns and side-chain matrix 
accessibility were observed when sucrose or guanidine hydrochloride was used as an excipient. 




glucagon-derived peptide to detect interactions with excipients and peptides in the solid state. 
Residue-level information about the preferred site of peptide-peptide crosslinking was obtained 
using tandem mass spectrometry. 
 
Although peptide-matrix interactions could be visualized using a photoactive amino acid (PAA) 
derivative within the primary sequence, incorporating an unnatural amino acid into larger proteins 
is fairly difficult and may alter higher order structure by disturbing intra-protein contacts. Therefore, 
a novel photo-crosslinking method was developed to further examine the solid-state environment 
of lyophilized proteins, described in Chapter 3. A heterobifunctional crosslinking reagent was used 
to crosslink the protein with the matrix in the solid state. Some loop regions showed increased 
peptide-peptide adducts, while helix E showed more hydration compared to other regions. In the 
presence of raffinose, water replacement was not detected in the solid state; instead there was 
some evidence of micro-phase separation without crystallization in the solid state. Thus local 
protein environment in the solid state could be probed without the need for PAA incorporation within 
the protein sequence. 
 
Lyophilization is an effective, yet expensive stabilization strategy, since conservative freeze-drying 
cycles often require long hours of drying. The stochastic nature of ice nucleation and lack of control 
over freezing can result in vial-to-vial heterogeneity due to differences in the degree of supercooling 
and ice crystal size. The research described in Chapter 4 focuses on using a variety of analytical 
methods to characterize lyophilized protein formulations to determine the effect of excipient and 
freezing step on protein structure. Myoglobin in the presence or absence of sucrose was lyophilized 
with or without controlled ice nucleation in a pilot-scale LyoStar freeze dryer. Ice nucleation 
occurred over a range of temperatures and times with uncontrolled nucleation, while controlled ice 
nucleation with rapid depressurization resulted in near-simultaneous ice nucleation. The sucrose-
containing formulation showed greater retention of protein structure by ssFTIR and solid-state 




homogeneity was observed in the sucrose-containing formulation by ssHDX-MS peak width 
analysis. No significant differences in secondary structure were detected between controlled and 
uncontrolled nucleation using ssFTIR and ssHDX-MS. Myoglobin lyophilized with controlled 
nucleation in the presence of sucrose showed the greatest side-chain labeling, as determined by 
ssPL-MS. The results show that high-resolution mass spectrometric methods can be used to study 
process- and excipient effects on protein structure. 
 
This thesis addresses limitations in current analytical methods used to characterize protein 
structure in the solid state. Whereas ssFTIR and DSC have lower sensitivity and provide 
information averaged over the entire sample, mass spectrometric methods can provide peptide-
level information about conformational changes occurring in a small subpopulation of protein. High-
resolution mass spectrometric methods have the potential to provide reliable and predictable 




CHAPTER 1. INTRODUCTION 
1.1 PROTEIN AGGREGATION IN THE SOLID STATE 
Protein drugs are an increasingly important sector in the pharmaceutical market. In 2009, the ten 
best-selling protein drugs had a combined sales value of close to $50 billion 1. The number of 
protein drugs on the market is expected to rise in the next few years, given the expiration of patents 
and growth of generic protein drugs or “biosimilars”. Protein instability is a major issue hampering 
formulation development, especially since each protein behaves uniquely in different environments. 
Formulation development for proteins is largely based on trial and error, making drug development 
very expensive and time-consuming. Many proteins are lyophilized to improve formulation stability. 
Although lyophilization confers greater stability on formulations compared to solution, degradation 
is known to occur in the solid state and during each step of the freeze-drying process 2-4. Protein 
aggregation is a serious problem in the clinical setting because it can reduce efficacy and 
compromise safety. Aggregation is also critical for the pharmaceutical industry, because it 
complicates the manufacturing and formulation process. Therefore it is important to characterize 
these lyophilized proteins at the conformational level to ensure integrity of protein structure, 
especially for biosimilars.  
 
Protein-side chains play an important role in the aggregation pathway. Intermolecular backbone 
and side-chain interactions facilitate the formation of amorphous aggregates 5, 6. Site-directed 
mutagenesis and molecular dynamic simulation (MDS) studies on peptides have implicated 
hydrophobic interactions between aromatic side-chains and electrostatic interaction through salt-
bridges in the formation and stabilization of amyloid fibrils 7-9. Hence it becomes important to 




proteins in solution and lyophilized formulations. It is especially difficult to follow aggregation in 
amorphous solids because of the inherent structural and spatial heterogeneity. Our lack of 
understanding of solid-state protein aggregation is compounded by the absence of robust, high-
resolution analytical methods, which makes it difficult to study protein stability at the molecular level. 
Traditional analytical techniques such as Fourier-Transform Infrared Spectroscopy (FTIR), Raman 
Spectroscopy and Differential Scanning Calorimetry (DSC) are semi-quantitative at best, suffer 
from low sensitivity and provide low-resolution information at the global level 10-12. Solid state 
Nuclear Magnetic Resonance spectroscopy (ssNMR) can provide site-specific information about 
conformational changes 13; however it requires extensive sample preparation using isotopic 
labeling and is also less sensitive to amorphous systems. Solid-state hydrogen-deuterium 
exchange in combination with mass spectrometry (ssHDX-MS) is an analytical tool that allows 
protein backbone environment to be probed with higher resolution. This technique has been used 
previously by our group to characterize formulations based on the amount of protection against 
exchange afforded by carbohydrate excipients 14. 
 
The aim of this dissertation is to characterize lyophilized protein structure and environment with 
high resolution. In our ongoing research program, we have developed two novel analytical 
techniques: ssPL-MS and ssPC-MS to probe protein side-chain environment in lyophilized 
formulations. These techniques have been used in molecular biology to map the interactome within 
cells 15-17. PL-MS has also been described for solution-state studies to probe protein topography 
and ligand binding 18, 19, while PC-MS is typically used to map the protein-protein interaction (PPI) 
interface in solutions 20, 21. To our knowledge, our research is the first application of PL-MS and PC-
MS to study molecular interactions in lyophilized solids. The research is significant to both industry 
and patients in several ways. These two high-resolution analytical methods can potentially identify 
local reactive sites participating in aggregation. Knowledge gained from these experiments can be 
used to design formulations rationally, by using excipients or chaperones that block reactive sites 




state environment that promotes protein stability and minimizes aggregation. Our novel technique 
is expected to detect aggregate-prone regions earlier than conventional analytical methods, which 
is important in mitigating patient risk and improving formulations in the early stages of development. 
This will also reduce the cost of formulation development and time to reach market, thus lowering 
the burden of healthcare on consumers. 
 
1.2 COVALENT LABELING OF PROTEINS 
Covalent labeling of proteins refers to the modification of amino acids by reaction with side-chain 
groups. The labeling agent contains a functional group that is reactive towards specific or non-
specific amino acids under certain conditions (e.g. alkaline pH or UV irradiation). Covalent labeling 
combined with mass spectrometry is a useful proteomics tool. It allows the side-chain environment 
to be mapped with high resolution and provides information about solvent (or matrix) accessibility 
of surface amino acids to the probe. The effect of excipients on protein tertiary structure can be 
determined by changes in labeling pattern. Labeling reagents may be classified as chemical or 
photolytic agents.  
 
1.2.1 Chemical Labeling Agents 
These probes undergo activation over a certain pH range and form covalent bonds with amino acid 
side chains in their proximity. The ratio of labeling agent to protein must be optimized to obtain a 
sufficient fraction of labeled protein without significantly perturbing protein structure. Previously 
used chemical agents include N-hydroxysuccinimide esters (NHS esters; amine specific), 2,3- 
butanedione (BD; Arg specific), N-alkylmaleimides (Cys specific) and diethylpyrocarbonate (DEPC; 
His, amine, hydroxyl specific). Although pH control ensures that the dominant reaction of the agent 
is with its target amino acid, sometimes side-reactions may occur and reduce the yield of the 
desired labeled amino acid. For example, BD is reactive towards Arg at pH 7-10; however it can 
also undergo photoactivation and react with Lys and His 22. Hence, reaction conditions may need 




Chemical labeling agents have been used to probe the structure of pre-aggregate species in 
solution. Mendoza et al. used three complementary labeling agents (NHSA, BD and DEPC) and 
examined the effect of β2 microglobulin (β2m) dimer formation on extent of amino acid modification 
in solution 19. About one-third of the surface amino acids and about one-half of the amino acids in 
the dimer interface were probed. The change in reactivity and extent of labeling of amino acids with 
increasing dimer formation was indicative of a change in the side-chain environment. Covalent 
labeling combined with molecular dynamic simulations suggested that residues with the greatest 
change in modification are likely present at or near the dimer interface. 
 
1.2.2 Photolytic Labeling Agents 
These probes undergo activation of certain functional groups on exposure to UV light. Activation 
leads to the formation of short-lived, unstable radicals or neutral molecules with unpaired electrons. 
These species readily participate in insertion or addition reactions with neighboring molecules with 
the formation of a new covalent bond. Photolytic analogs of amino acids have been synthesized to 
study protein-protein interactions. These photolytic amino acids (PAAs) can be inserted into protein 
and peptide sequences through mutagenesis, translational incorporation during protein expression 
or solid-phase synthesis. The most common photoactive moieties in PAAs are arylazides, 
diazirines and benzophenones. 
 
1.2.2.1 Arylazides 
Arylazides are activated when exposed to UV light below 310 nm, forming reactive singlet nitrenes 
(lifetime ~ 1 ns) with expulsion of molecular nitrogen. Nitrenes can undergo ring expansion to form 
dehydroazepines that are particularly reactive towards nucleophilic amines and form covalent 
adducts. Nitrenes can also add to unsaturated bonds or insert into C-H and N-H bonds. The main 
disadvantage of crosslinking proteins with arylazides is possible damage to proteins at the 





Diazirine-containing PAAs such as 2-amino 4,4’ azipentanoic acid (photo-leucine, pLeu) and L-2-
amino-5,5-azi-hexanoic acid (photo-methionine, pMet) undergo activation at higher wavelengths 
than arylazides. At 350-365 nm, the diazirine ring loses molecular nitrogen and forms an active 
carbene species. The lifetime of the carbene is very short (on the order of nanoseconds) and it 
undergoes insertion into any C-C and X-H bond (X= C, H, N, O, S) or addition on to a C=C bond in 
its immediate molecular cage (Fig. 1.1). Thus carbenes do not show preference for any particular 
amino acid and are expected to label any surface residue indiscriminately. Other reactions of 
carbenes include quenching by water to form a hydroxy derivative and self-interaction to form an 
alkene. 
 
Figure 1.1. Schematic showing reactions of carbene formed upon activation of pLeu (reprinted with 
permission from ‘Mass Spectrometry of Laser-Initiated Carbene Reactions for Protein Topographic 





Photolytic labeling- mass spectrometry (PL-MS) with pLeu has been reported in solution for 
myoglobin (Mb) and calmodulin (CaM) using a 1:10,000 molar ratio of protein to pLeu and a pulsed 
laser for irradiation 18. CaM was detected carrying up to 4 labels, while Mb showed up to 2 labels. 
PL-MS was sensitive to changes in CaM conformation upon ligand binding, with ~ 39 % reduction 
in labeling for the ligand-bound protein compared to free CaM. 
 
1.2.2.3 Benzophenones 
In contrast to diazirines, benzophenone-containing PAAs (e.g. p-benzoyl L-phenylalanine; pBpA) 
appear to have greater affinity for electron-rich residues. Upon exposure to UV-A light, the carbonyl 
group on the benzophenone is activated to a diradicaloid triplet state (with a lifetime of 80-100 μs 
in the absence of an H-donor) 23. The oxygen radical abstracts a hydrogen atom from a suitably 
oriented C-H group in its vicinity and forms a ketyl radical (Fig. 1.2). The hydrogen-deficient alkyl 
radical and the ketyl radical recombine to form a covalently bonded adduct. Effective H-donors 
include C-H bonds in Leu and Val and CH2 groups adjacent to heteroatom containing amino acids 
like Met, Arg and Lys 23. Unlike diazirines, activation of benzophenones is reversible. The 
diradicaloid species relaxes to its ground state in the absence of a suitably oriented H-donor. Thus, 
adduct formation may take a long time with several excitation-relaxation cycles until a favorable 





Figure 1.2. Schematic depicting covalent bond formation between a benzophenone- containing 
PAA and an amino acid on exposure to UV-A light (adapted from 23). 
 
1.3 CROSSLINKING OF PROTEINS 
Crosslinking refers to the formation of a new intramolecular or intermolecular covalent bond 
between two amino acid side chains. This may be achieved by chemical and/or photolytic means. 
Crosslinkers may contain one functional group (e.g. 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride; EDC), but usually are homobifunctional or heterobifunctional. 
Homobifunctional crosslinkers (e.g. disuccinimidyl suberate; DSS) contain identical functional 
groups at each end of a spacer arm. They must be used in a single-step reaction since they react 
identically with their target group (e.g. amine to amine crosslinking), hence they are not very precise. 
Heterobifunctional crosslinkers (e.g. succinimidyl 4,4’- azipentanoate, SDA) have two different 
reactive groups at each end of a spacer arm and hence can be used to crosslink two specific 
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precision than homobifunctional agents. Step 1 involves reaction of one end of the crosslinker with 
its target side chain (e.g. amine-reactive succinimidyl ester). After the reaction is complete, the 
excess unreacted crosslinker is removed by dialysis or desalting. Step 2 involves activation of the 
other end of the crosslinker (e.g. sulfhydryl-reactive N-alkylmaleimide) which results in formation of 
covalently linked adducts. Semi-specific labeling can be achieved by using a heterobifunctional 
crosslinker with a chemically reactive functionality at one end of the spacer and a photoactive 
functionality at the other end. For example, SDA contains an amine-reactive NHS-ester moiety at 
one end and a non-specific diazirine ring at the other end (Fig. 1.3).  
 
Figure 1.3. Schematic illustrating mechanism of crosslinking two proteins using the 
heterobifunctional photoactive crosslinker succinimidyl 4,4’- azipentanoate (SDA) (adapted from 
Life Technologies https://www.lifetechnologies.com/order/catalog/product/26167). 
 
Spacer arms are usually carbon chains, but may also include reducible disulfide bonds. The length 
of the spacer arm determines steric effects and limits the number of crosslinked adducts formed. 
Cross-linkers may be classified based on the length of the spacer arm. Zero-length cross-linkers 
have no spacer arm and form a direct covalent bond between two molecules without themselves 






















conjugate carboxyl groups and amine groups via an amide bond. In general, short spacer arms (4-
8 Å) are better suited to study intramolecular crosslinks, while long spacer arms (~ 12 Å) favor 
intermolecular crosslinks. The spacer arm may also be cleaved to facilitate separation of the 
crosslinked species and reduce the complexity of MS analysis.  
 
PAAs with a single active functionality can also be used for crosslinking. Peptides and proteins with 
a PAA incorporated within the amino acid sequence can be irradiated to produce cross-linked 
molecules. Kolbel et al observed differences in crosslinking patterns as a function of secondary 
structure using peptides containing pLeu within the primary sequence 20. Similarly, changes in the 
conformation of the receptor PPAR-α upon agonist and antagonist binding were observed using 
genetically encoded pBpA incorporated within the sequence of PPAR-α 24. In addition, PAAs 
incorporated within the protein sequence using the translational machinery of cells have been used 
to map the intracellular interactome 15, 25, 26.  
 
Crosslinking with mass spectrometry can provide useful, high-resolution information about 
interacting partners and binding interfaces. Gomes and Gozzo used an HPP (succinimidyl 2-[(4,4´-
azipentanamido)ethyl]-1,3´-dithioproprionate (SDAD) to crosslink Mb 27. SDAD has an NHS ester 
at one end and a diazirine ring at the other, separated by a 13.6 Å spacer arm with a cleavable 
disulfide bond. The NHS moiety was reacted first at alkaline pH, followed by removal of excess 
unreacted SDAD. The labeled protein was irradiated to activate the diazirine end, resulting in 
formation of crosslinked products. The spacer arm was cleaved by reduction to facilitate analysis. 
Both intra- and intermolecular crosslinks were detected by MS analysis. Furthermore, the sites of 
crosslinking could be localized using MS/MS.  
 
Although crosslinking improves resolution of side-chain environment, it also increases the 
complexity of data, especially when there are multiple crosslinks within the same peptide. In order 




the type of product formed 28. Internal rearrangement or quenching of the activated labeling agent 
result in Type 0 ‘deadend’ modifications. The reactive probe may also label an amino acid within 
the same polypeptide chain, forming a Type 1 intrapeptide crosslink. Reaction of the label with an 
amino acid belonging to another protein molecule results in a Type 2 interpeptide crosslink between 
a longer peptide (α) and a shorter peptide (β). Additionally, various combinations of these 
modifications are also possible, making data analysis complicated. 
 
 
1.4 ADVANTAGES OF MODIFICATION USING PAAs 
PAAs offer a number of advantages over chemical labeling agents. For example, since labeling is 
not biased towards a particular amino acid, the entire protein surface can be probed. In addition, 
small PAAs like pLeu and pMet can be incorporated into the sequence of the protein through 
metabolic labeling. The PAAs simply need to be added to cell culture media instead of their wild-
type counterpart, and the cells’ translational machinery will incorporate the PAA into the protein 
sequence. Thus the modified proteins themselves can be used as labeling agents. Furthermore, 
UV irradiation allows PAAs to be added to the reaction mixture prior to activation. It also provides 
better control of reaction than chemical agents such as NHS that require pH control and quenching 
of excess reagent. 
 
1.5 ADVANTAGES OF CROSSLINKING 
Thus far, indirect evidence of solid-state protein-excipient and protein-water interactions has been 
reported using FTIR spectroscopic data29, 30. These inferences are based on band areas for 
carboxylate hydrogen-bonding interactions. A disadvantage of FTIR is that band resolution 
depends on arbitrary deconvolution input parameters such as half-bandwidth, resulting in altered 
peak position and intensity for the same spectrum. Solid-state crosslinking allows for direct 
interrogation of protein-matrix interactions using mass spectrometry. High-resolution qualitative 




different formulations can be obtained. An additional advantage is lack of interference from water 
vapor. 
 
1.6 SPECIFIC AIMS 
The inherent instability of proteins makes the formulation of biologics challenging. Formulation 
development is often done by a trial and error approach, which can be time-consuming and 
expensive. In addition, analytical methods currently used to characterize protein structure lack 
sufficient resolution, making it difficult to draw meaningful conclusions about conformation. In this 
research, two novel analytical methods, solid-state photolytic labeling-mass spectrometry 
(ssPL-MS) and solid-state crosslinking-mass spectrometry (ssPC-MS) are being developed. 
The overall objective of this research is to develop ssPL-MS and ssPC-MS as tools for rational 
protein formulation, supplanting the current paradigm of trial and error. PL-MS using 
photoreactive amino acid analogs (PAAs) has been described for solution samples, to study 
protein-protein interaction in vitro as well as in vivo 15, 18, 20. Similarly, PC-MS using 
heterobifunctional photoactive probes (HPPs) has been used to elucidate the three-dimensional 
structure and molecular interactions of proteins 27, 31, 32. This proposal aims to adapt PL-MS and 
PC-MS to the solid state (ssPL-MS and ssPC-MS) for lyophilized formulations. A photoactive 
labeling or crosslinking reagent (PAA/HPP) will be used to probe the protein side chain environment 
in three different ways; (a) PAA incorporated in the lyophilized formulation matrix as an excipient 
and then irradiated (external labeling), (b) PAA incorporated within a protein/peptide sequence and 
then lyophilized (internal labeling) and (c) Protein side-chains derivatized with HPP, lyophilized and 
irradiated (crosslinking). When the PAA/HPP is irradiated with UV light (350-365 nm), the 
photoreactive functional group on the probe is activated and reacts with protein molecules in its 
vicinity (within a certain distance). As a result, a covalent bond is formed between the PAA/HPP 
and protein side chain. The labeled/crosslinked protein is analyzed by MS at the intact level and 





Labeling and crosslinking can provide direct information about the local environment of amino 
acid side-chains in protein formulations. This makes the method complementary to hydrogen-
deuterium exchange mass spectrometry (HDX-MS), which probes secondary structure. The 
location of the label can identify side-chains on the protein that are accessible to the PAA/HPP. 
The three dimensional structure of a protein or protein complex can also be elucidated, since the 
crosslinking reaction is constrained by distance. An added advantage is the absence of back-
exchange of the label, which is a limitation of HDX-MS.  
 
SPECIFIC AIM 1. To probe protein-protein and protein-matrix interactions in lyophilized 
protein formulations using external photolytic labeling and crosslinking. 
In order to rationally design a lyophilized protein formulation, high-resolution, molecular-level 
information about the protein and surrounding matrix is required. To obtain this information, two 
approaches will be used (i) a PAA probe will be added to the excipient matrix in lyophilized 
formulations and irradiated with UV-A light (365 nm) to form covalent bonds between the probe and 
neighboring protein molecules. The protein-PAA adducts will be analyzed by LC-MS at the intact 
protein level and at the peptide level (ii) a PAA probe will be incorporated within a peptide sequence 
and lyophilized with excipients. Crosslinking will be initiated by UV irradiation and peptide-peptide 
and peptide-excipient adducts will be analyzed by LC-MS at the intact protein level and at the 
peptide level. The studies test the hypothesis that ssPL-MS and ssPC-MS can detect protein-
protein and protein-matrix interactions. 
 
SPECIFIC AIM 2. To probe protein conformation, protein-protein and protein-matrix 
interactions in solids and solutions using crosslinking. 
The goal of Specific Aim 2 is to crosslink a model protein with matrix components in lyophilized 
formulations. Complementary to Specific Aim 1, this research allows detection of protein-protein, 
protein-excipient and protein-water adducts in the solid state. Myoglobin will be derivatized with a 




crosslinker will be irradiated in the solid state to produce crosslinked adducts. ESI-HPLC-MS will 
be used to identify these adducts after trypsin digestion. The studies test the hypothesis that 
changes in protein-protein and protein-matrix interactions can be detected with high resolution in 
different lyophilized formulations using ssPC-MS. 
 
SPECIFIC AIM 3. To study the effect of process and excipient on lyophilized protein 
conformation using mass spectrometric methods.  
Processing conditions can affect protein structure and result in instability during lyophilization, 
storage or reconstitution. Specific Aim 3 focuses on detection of conformational changes in the 
solid-state using high-resolution analytical methods. Myoglobin will be lyophilized with and without 
controlled ice nucleation in a pilot-scale freeze-dryer. Product temperature will be monitored during 
lyophilization and conventional product characterization techniques such as FTIR spectroscopy 
and moisture content analysis will be performed. Backbone conformational changes will be 
monitored using solid-state hydrogen deuterium exchange-mass spectrometry (ssHDX-MS) and 
side-chain matrix accessibility will be assessed using solid-state photolytic labeling- mass 
spectrometry (ssPL-MS). The hypothesis is that these high-resolution methods are more sensitive 
to structural changes than conventional solid-state FTIR spectroscopy. 
 
1.7 OVERALL APPROACH 
Model Proteins and Peptides: Myoglobin will be used as a model protein for Specific Aim 1, 2 
and 3, as it is a fairly small molecule with no cysteines and has also been used for ssHDX studies 
in our lab previously. Hence enzymatic digestion and MS analysis will be relatively straightforward. 
A glucagon-derived peptide (GDP) obtained from the N- terminus of glucagon (1-HSQGTFTS-8; 
hereafter referred to as GCG (1-8)*) will be used for Specific Aim 1 for internal labeling experiments. 
The PAA probe p-benzoyl-L-phenylalanine (pBpA) will replace Phe in GCG (1-8)*. This peptide 





Photo amino acid analogs (PAAs) as probes: The PAA probes to be used are L-photo-leucine 
(L-2-amino-4,4-azipentanoic acid; pLeu), L-photo-methionine (L-2-amino-5,5-azi-hexanoic acid; 
pMet) ((Pierce Biotechnology, Rockford, IL) and p-benzoyl-L-phenylalanine (pBpA) (Bachem, 
Torrance, CA).  These PAAs have different reaction mechanisms upon exposure to UV light at 350-
365 nm; the diazirine functional group of pLeu and pMet forms a reactive carbene intermediate that 
inserts non-specifically into any C-C and X-H bond (X= C, H, N, O, S) or adds on to a C=C bond in 
its immediate molecular cage 18. Labeling with pLeu and pMet is quite promiscuous, as the carbene 
intermediate does not favor a particular amino acid. On the other hand, the benzophenone group 
in pBpA forms a reactive ketyl radical that reacts preferentially with C-H bonds and forms new C-C 
covalent linkages 23. Besides these PAAs, an HPP succinimidyl 4,4’ azipentanoate (NHS-diazirine; 
SDA) will also be used. SDA contains an N-hydroxysuccinimide (NHS) ester that reacts with 
primary amines at alkaline pH to form an amide bond. It also contains a second functional group, 
a photoactive diazirine ring that forms a carbene upon exposure to UV-A light and reacts with any 
amino acid side-chain. The two groups are connected by a short (3.9 Å) carbon chain spacer arm. 
 
Data analysis: In silico digestion of labeled proteins can be performed in MassHunter software as 
well as others such as the FindPept tool (ExPASy). This theoretical list can be matched with the 
observed masses using MassHunter. Analysis of cross-linked peptides is more challenging 
because the fragment ions obtained by MS/MS are also cross-linked. This greatly increases the 
complexity of the data and manual assignment of masses often must be made. The software 
GPMAW can compute the mass of possible crosslinked peptides after data is provided for the 
primary sequence of the crosslinked proteins, the type of crosslinker and the enzyme used for 
digestion. XQuest and XLink assign m/z values to MS/MS fragment peaks and can be used to 
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CHAPTER 2. PHOTOLYTIC LABELING TO PROBE MOLECULAR INTERACTIONS IN 
LYOPHILIZED POWDERS 
This chapter was published as a research article in Molecular Pharmaceutics (2013) and can be 
found online at http://pubs.acs.org/doi/abs/10.1021/mp4004332 
 
2.1 ABSTRACT 
Local side-chain interactions in lyophilized protein formulations were mapped using solid-state 
photolytic labeling-mass spectrometry (ssPL-MS). Photoactive amino acid analogs (PAAs) were 
used as probes and either added to the lyophilized matrix or incorporated within the amino acid 
sequence of a peptide. In the first approach, apomyoglobin was lyophilized with sucrose and 
varying concentrations of photo-leucine (L-2-amino-4, 4’-azipentanoic acid; pLeu). The lyophilized 
solid was irradiated at 365 nm to initiate photolabeling. The rate and extent of labeling were 
measured using ESI-HPLC-MS, with labeling reaching a plateau at ~ 30 min, forming up to 6 
labeled populations. Bottom-up MS/MS analysis was able to provide peptide-level resolution of the 
location of pLeu. ssPL-MS was also able to detect differences in side-chain environment between 
sucrose and guanidine hydrochloride formulations. In the second approach, peptide GCG (1-8)* 
containing p-benzoyl-L-phenylalanine (pBpA) in the amino acid sequence was lyophilized with 
various excipients and irradiated. Peptide-peptide and peptide-excipient adducts were detected 
using MS. Top-down MS/MS on the peptide dimer provided amino acid-level resolution regarding 
interactions and the cross-linking partner for pBpA in the solid state. The results show that ssPL-






Protein drugs are an increasingly important part of the global pharmaceuticals market. In 2009, the 
ten best-selling protein drugs had a combined sales value of close to $50 billion1. The number of 
approved protein drugs is expected to increase in the next few years, particularly given the 
expiration of patents and the growth of biosimilars. According to a report by Global Industry 
Analysts, Inc., biosimilars are expected to be valued at $17.9 million by 20172. However the 
inherent instability of proteins and their tendency to aggregate is an obstacle to the development 
of these life-saving medicines. In an attempt to maintain stability and provide adequate shelf life, 
many proteins are lyophilized. In addition to those products marketed as lyophilized powders, the 
protein itself may be lyophilized for storage prior to final formulation in either solution or solid forms. 
Although lyophilized formulations usually confer greater stability when compared to solution, 
degradation may still occur in the solid state and during the freeze-drying process3-6.  Retention of 
native protein structure in the lyophilized solid has generally been associated with improved stability 
during shelf-storage and a decreased propensity for aggregate formation7-9. Ensuring the retention 
of native conformation would benefit from analytical methods that could identify subtle protein 
structural perturbations in lyophilized solids with high resolution. Such information could be used to 
design formulations rationally and to screen candidate formulations efficiently. 
 
Most of the current analytical techniques used to characterize proteins in the solid state lack 
sufficient resolution to serve as design tools, however. Methods such as Fourier transform-infrared 
spectroscopy (FTIR), Raman spectroscopy and differential scanning calorimetry (DSC) have been 
used to study structural changes in lyophilized proteins10-13. These methods are semi-quantitative 
at best, suffer from low sensitivity and can provide only low-resolution information on protein 
structure. Solid-state nuclear magnetic resonance spectroscopy (ssNMR) can provide site-specific 
information about conformational changes14, 15, but requires extensive sample preparation and 
isotopic labeling, and is less sensitive in amorphous samples than in those that are crystalline. 




Recently, our group has developed solid-state hydrogen-deuterium exchange with mass 
spectrometric analysis (ssHDX-MS) to allow the protein environment in amorphous solids to be 
probed with higher resolution. ssHDX-MS provides structural information with peptide level 
resolution, and has been used previously by our group to characterize protein conformations in 
lyophilized solids containing various excipients16, 17. 
 
In the work reported here, we have developed a complementary analytical technique, solid-state 
photolytic labeling with mass spectrometric analysis (ssPL-MS), to probe protein structure and 
matrix interactions in lyophilized formulations. In solution, PL-MS with photoreactive amino acid 
analogs (PAAs) has been used to study protein/peptide conformation and protein-protein 
interactions (PPIs)18-20. The approach has also been used in living cells to map the interactome21-
23. In solution PL-MS, a solution containing protein and PAA is irradiated with UV light (350-365 
nm), activating the PAA photoreactive functional group, which then forms a covalent bond between 
the PAA and protein in its immediate vicinity. The labeled protein is analyzed by MS at the intact 
protein level and by MS/MS fragmentation after enzymatic digestion (bottom-up) or direct 
fragmentation (top-down). The location of the label identifies sites on the protein that are accessible 
to the photoreactive probe, providing information about the side-chain environment. This makes 
the method complementary to HDX-MS, which probes backbone environment and secondary 
structure. Moreover, the covalently attached label is permanent and does not undergo back-
exchange, a limitation of HDX. Solution state PL-MS has also been carried out by incorporating the 
PAA within a protein or peptide sequence19, 24. Exposure to UV light generates photoadducts of the 
PAA-containing protein/peptide with interacting molecules (e.g. ligand) in the microenvironment. 
These photoadducts can then be digested enzymatically and analyzed to identify the reactive sites 
at the interface of the complex.  
 
In the current work, we have adapted PL-MS for proteins in lyophilized solids. PAAs were used to 




lyophilized solid as an excipient and (ii) by incorporating a PAA into the sequence of a model 
peptide. In studies using a PAA probe as an excipient (i), apomyoglobin (ApoMb) was selected as 
a model protein and L-photo-leucine (L-2-amino-4, 4’-azipentanoic acid; pLeu) was used as an 
excipient. In studies with the PAA incorporated into the protein sequence (ii), an octapeptide 
derived from the N-terminus of human glucagon (1-HSQGTFTS-8) with the phenylalanine residue 
(F6) replaced by the PAA p-benzoyl-L-phenylalanine (pBpA) was used. The two PAAs have 
different reaction mechanisms upon exposure to UV light. The diazirine functional group of pLeu 
forms a reactive carbene intermediate that inserts non-specifically into any C-C or X-H bond (X= C, 
N, O, S), or adds to a C=C bond in its immediate molecular cage. The benzophenone group in 
pBpA forms a reactive ketyl radical that reacts preferentially with C-H bonds and forms new C-C 
covalent linkages25, 26. The results demonstrate that photolytic labeling occurs in lyophilized solids 
when the label is either incorporated into the matrix (i) or into a model peptide (ii). The results also 
show that the extent of labeling varies with position in the protein sequence and with solid 
composition. To our knowledge, this is the first reported use of photolytic labeling to map the protein 
environment in lyophilized solids. The findings support further development of the method to probe 
the amorphous solid state and in formulation development. 
 
2.3 MATERIALS AND METHODS 
Apomyoglobin (apoMb) from equine skeletal muscle, monobasic and dibasic potassium hydrogen 
phosphate, L-methionine (Met), L-leucine (Leu), sucrose, trehalose, urea and guanidine 
hydrochloride were purchased from Sigma Aldrich (St. Louis, MO). L-photo-leucine (L-2-amino-4, 
4-azipentanoic acid; pLeu) was obtained from Thermo Scientific (Rockford, IL). An octapeptide 
derived from the N-terminus of glucagon (HSQGT-pBpA-TS; henceforth referred to as GCG (1-8)*) 
containing the photoreactive amino acid p-benzoyl-L-phenylalanine (pBpA) within its sequence was 
synthesized by American Peptide Company (Sunnyvale, CA) and received as a lyophilized powder. 
Trypsin and chymotrypsin were purchased from Promega (Madison, WI) and mass spectrometry-




2.3.1 Sample Preparation 
ApoMb was dissolved in potassium phosphate buffer (20 mM, pH 7.4) to produce a stock solution 
of 200 µM protein and the solution was dialyzed using Biotech Cellulose Ester dialysis tubing 
(MWCO 8,000-10,000 Da, Spectrum Laboratories, Rancho Dominguez, CA) for 24 h into the same 
buffer. After dialysis, the solution was filtered through a 0.2 µm syringe filter (Gelman Nylon 
Acrodisc 13) and used for further experiments. Sucrose stock solution (33.9 mg/mL) was prepared 
by dissolving sucrose in potassium phosphate buffer and filtering through a 0.2 µm syringe filter. 
The resulting solution was stored at 4 °C until use. A stock solution of pLeu (30 mM) was prepared 
similarly. Lyophilization was carried out with different ratios of protein to pLeu using a VirTis Plus 
AdVantage freeze dryer (SP Industries Inc., Gardiner, NY). ApoMb, sucrose and pLeu stock 
solutions were mixed such that the final protein concentration was 100 µM, the protein to sucrose 
ratio was 1:2 w/w and the protein to pLeu molar ratio was 1:20, 1:50 or 1:100. Control samples 
contained apoMb and sucrose without pLeu. The final volume for lyophilization was 80 µL. In order 
to produce a pharmaceutically relevant formulation, ~ 50 % or more of the solid matrix consisted of 
sucrose, and buffer was less than 10 % of the formulation by weight (Table 2.1).  
 
All samples were lyophilized in vials made of borosilicate clear glass using an established 
conservative freeze-drying cycle. During the lyophilization cycle, the shelves were precooled to -
2 °C. Freezing was carried out at -40 °C for 50 min, followed by drying under vacuum (70 mTorr) 
over 5 steps (-35 °C for 10 h, -20 °C for 8 h, -5 °C for 6 h, 10 °C for 6 h and 25 °C for 6 h). The 











ApoMb Sucrose pLeu Buffer 
No pLeu 31.0 61.9 0.0 7.1 
1:20 29.4 58.5 5.0 6.8 
1:50 27.4 54.8 11.6 6.3 
1:100 24.5 49.1 20.7 5.6 
 
2.3.2 Photolytic Labeling and MS Analysis of Intact Protein 
Photolytic labeling was carried out using a UV Stratalinker 2400 equipped with five 365 nm UV 
lamps (Stratagene Corp., La Jolla, CA). The lamps were allowed to warm up for 5 min. Vials 
containing lyophilized samples and solution controls were uncapped and placed inside the UV 
chamber. The distance between the lamps and the cake at the bottom of the vial was approximately 
15 cm. All samples were irradiated with UV light for 40 min. After irradiation, the solid was 
reconstituted with 800 µL of Solution A (A= 0.1 % formic acid in MS water) to give a final protein 
concentration of 10 nmol/mL. The solution formulation was diluted similarly. The samples were 
diluted further with Solution A and 20 pmol of protein was injected into the HPLC-MS system. Intact 
labeled protein was analyzed using HPLC-MS equipped with an ESI source (1200 series LC, 6520 
qTOF; Agilent Technologies, Santa Clara, CA). Mass spectra were processed and deconvoluted 





Percentages of protein populations with 1 through 6 labels were calculated using peak heights from 
extracted ion chromatograms: 
 
  % Li = PHi/ (PHi + PHu) x 100     Equation 2.1  
 
where i denotes the number of labels (1-6), PHi denotes the peak height for labeled protein Li and 
PHu denotes the peak height of the unlabeled protein as observed by mass spectrometry. 
Hereinafter, the term ‘unlabeled’ will refer to a protein/peptide that has been exposed to pLeu and 
irradiation, but was not labeled, while the term ‘native’ will refer to a protein/peptide that has not 
been exposed to pLeu and irradiation. 
 
2.3.3 Effect of Irradiation Time and pLeu concentration on Labeling Efficiency 
ApoMb lyophilized with sucrose and pLeu (1:100 molar ratio protein: pLeu, which is equivalent to 
20.7 % w/w pLeu) was used to study the kinetics of photolytic labeling. Lyophilized samples were 
subjected to photolysis for different periods of time (0, 0.5, 2, 4, 10, 20, 30, 40 and 60 min). The 
samples were reconstituted and analyzed as described above. In a separate study, apoMb was 
lyophilized with sucrose and varying pLeu concentrations (0, 0.3, 1.3, 1.5, 2.5, 11.6 and 20.7 % 
w/w). The solid was irradiated at 365 nm for 40 min, reconstituted and analyzed for labeled protein. 
The fraction of labeled protein (FL) was calculated using peak heights from extracted ion 
chromatograms: 
 
  FL = 1 – [PHu/(PHu + PHL)]     Equation 2.2   
 
where PHL denotes the peak height for labeled protein and PHu denotes the peak height of the 
unlabeled protein as observed by mass spectrometry. FL represents the sum of populations of 




2.3.4 MS- and MS/MS- Analysis of Labeled apoMb Peptides 
To identify the sites of photolytic labeling, apoMb was lyophilized with sucrose and pLeu as 
described above using 0, 0.3, 1.3, 1.5, 2.5, 11.6 and 20.7 % w/w pLeu. The solid was irradiated at 
365 nm for 40 min and then reconstituted in ammonium bicarbonate buffer (100 µM, pH 8.0) to give 
a protein concentration of 10 nmol/mL. Enzymatic digestion of labeled apoMb was performed for 
24 h at 60 oC using a combination of trypsin and chymotrypsin (1:1 molar ratio) at a total enzyme 
to protein molar ratio of 1:10. The reaction was then quenched with solution A and 20 pmol was 
injected into the LC-MS system. The proteolytic fragments were separated on a ZORBAX 300SB-
C18 column (Agilent Technologies; 1.0 x 50 mm, particle size 3.5 µm). The column was equilibrated 
with 5% Mobile Phase B (B= 0.1 % formic acid in acetonitrile) and peptides were eluted at 50 
µL/min using a gradient that increased from 5 to 45% B over 22 min and then from 45 to 95% B 
over 0.5 min. Mass spectra were processed using MassHunter and a theoretical digest map (with 
known sites of enzymatic cleavage, and allowing for up to 8 missed cleavages) was used to create 
a mass list for peptides carrying 0 through 7 labels. This theoretical list was matched against mass 
values obtained experimentally. 
 
Based on this analysis, up to 15 labeled peptides were detected that carried one, two or four labels. 
One of these peptides, L32-K42 (LFTGHPETLEK) with one label was selected for MS/MS analysis. 
This precursor peptide had m/z = 462.9133 (z = +3) and was subjected to fragmentation using low-
energy CID (Agilent Technologies), which predominantly produces b- and y-ions. Product ions were 
identified using MassHunter software. 
 
2.3.5 Formulation Effects 
In order to study the effect of excipients on side-chain environment, apoMb was lyophilized with 
100x molar excess of pLeu in two formulations: the first with sucrose (1:2 w/w ratio of protein to 
sucrose) and the second with guanidine hydrochloride (Gdn HCl; 1.5 M final concentration). The 




formulation) or ~ 1 % w/w (Gdn HCl formulation). The lyophilized formulations were subjected to 
photolysis at 365 nm for 40 min. After reconstitution with ammonium bicarbonate buffer, the 
samples were digested with trypsin and chymotrypsin and peptide-level MS analysis was carried 
out as described above. 
 
2.3.6 Photolytic Labeling with p-Benzoyl-L-Phenylalanine (pBpA) 
GCG (1-8)* was dissolved in water to give a final concentration of 1 mM. The peptide was 
lyophilized alone or with one of the following excipients: sucrose, trehalose, urea, L-methionine and 
L-leucine (1:2 w/w ratio of peptide to excipient). After lyophilization, the formulations were irradiated 
with UV light (365 nm) for 30 min. The irradiated samples were then reconstituted in 200 μL of MS 
water containing 0.1 % formic acid. Solution controls prepared with or without excipients were 
lyophilized and reconstituted before irradiation. The samples were further diluted to 20 pmol of 
peptide for injection into the LC-MS system. MassHunter software was used to detect peptide-
peptide and peptide-excipient adducts. 
 
Photolytic labeling with GCG (1-8)* was also carried out with pLeu in the matrix. Two formulations 
were prepared. The first contained GCG (1-8)* and pLeu at a 1:1 molar ratio, while the second 
contained GCG (1-8)* and pLeu at a 1:1 molar ratio, together with sucrose (1:2 w/w ratio of GCG 
(1-8)* to sucrose). Both formulations were lyophilized as described above, irradiated with UV light 
for 30 min, reconstituted and analyzed by ESI-LC-MS. Solution controls were prepared and 
analyzed as described above. 
 
2.3.7 MS/MS Analysis of GCG (1-8)* Dimer 
Both lyophilized and solution formulations showed the presence of GCG (1-8)* dimer. LC-MS/MS 
was carried out on GCG (1-8)* monomer (m/z 968.41, z= +1) and GCG (1-8)* dimer (m/z 646.28, 




b- and y-ions were monitored. The dimer from solution controls (unlyophilized solution and 
lyophilized-rehydrated solution) was also analyzed by MS/MS. 
 
2.4 RESULTS 
2.4.1 Intact Protein Labeling 
The mechanisms of photolytic labeling with pLeu in solution are well understood18, 25. Briefly, 
photolysis of pLeu at 365 nm results in the loss of N2 with the generation of a reactive carbene. The 
carbene labels any C-C, C=C or X-H group (X=C, O, N, S) in its proximity without bias towards a 
particular amino acid or functional group. Photolabeling of myoglobin with pLeu has been carried 
out in solution, with successful labeling at a 1:10,000 molar ratio of protein to pLeu18. Here, we 
investigated the covalent labeling of apoMb with pLeu in lyophilized solids. Intact protein was co-
lyophilized with sucrose and pLeu as excipients in weight fractions that are pharmaceutically 
relevant.  
 
Mass spectrometric analysis of lyophilized solids containing apoMb and pLeu showed that carbene 
labeling also occurs in the solid state. Peaks corresponding to labeled protein were observed, with 
masses differing by multiples of ~115 amu (Fig. 2.1). The extent of labeling depended on the 
amount of pLeu in the matrix. Peaks corresponding to singly- and doubly-labeled apoMb 
populations were observed when apoMb was lyophilized with a 20-fold molar excess of pLeu (Fig. 
2.1). Similarly, peaks corresponding to up to 4 and 6 labels per protein molecule were observed for 
the 1:50 and 1:100 formulations, respectively. ApoMb lyophilized without pLeu showed no adduct 
formation after irradiation (data not shown), confirming that UV light did not cause protein cross-
linking. Also, protein lyophilized with pLeu showed no labeling in the absence of UV light (data not 
shown). Moreover, solution controls showed no labeling of apoMb with 20-, 50-, 100- or 1000-fold 
molar excess of pLeu (data not shown), suggesting that the reactive carbene species was 





Figure 2.1 Deconvoluted mass spectra of native ApoMb (N) and ApoMb co-lyophilized with sucrose 
(1:2 w/w ratio of protein to sucrose) and pLeu in molar ratios 1:20, 1:50 and 1:100. Mass spectra 
show peaks for unlabeled apoMb (U) and labeled apoMb (nL) (n=1-6). The peaks differ by ~ 115 
amu, corresponding to the mass of one pLeu label. 
 
2.4.2 Labeling Kinetics 
During exposure of solid samples to UV irradiation, the fraction of labeled protein increased with 
time (Fig. 2.2A). The rate of formation of labeled protein was rapid initially and plateaued at ~30 
min with ~20% of the protein remaining unlabeled (Fig. 2.2A). Labeling followed monoexponential 
kinetics as a function of irradiation time. To determine the effect of pLeu concentration on the 
plateau value, the extent of labeling was measured at different initial concentrations of pLeu with 
40 min of irradiation (Fig. 2.2B). At 0 % w/w pLeu, no labeling occurred. As pLeu concentration was 
increased, the fraction of labeled protein increased until at 20.7 % w/w pLeu, ~35 % unlabeled 
protein remained after 40 min of irradiation. The dependence of the extent of modification on pLeu 
concentration also followed monoexponential behavior.  
 
An exponential model was used to simultaneously fit the rate and extent of labeling: 
  FL(C, t) = A(1-e-k1t)(1-e-k2C)     Equation 2.3  




































where FL(C, t) is the fraction of labeled protein as a function of pLeu concentration (C) and 
irradiation time (t), k1 and k2 are apparent first-order rate constants for the rate and extent of labeling, 
respectively, and A is the fraction of protein labeled at plateau. Nonlinear regression (Origin Pro 
v.8.6, OriginLab, Northampton, MA; n = 48) returned values of the regression parameters of A = 
0.82 (±0.03), k1= 0.22 min-1 (±0.02) and k2= 0.12 mM-1 (±0.01). 
 
Figure 2.2. (A) Kinetics of photolytic labeling of apoMb in lyophilized solids containing 20.7 % w/w 
pLeu in the matrix, 365 nm irradiation. The solid line is fit to Eqn. 2.3. n = 3 ± SD. (B) Dependence 
of ApoMb photolytic labeling on the concentration of pLeu after 40 min irradiation at 365 nm. The 
solid line is fit to Eqn. 2.3. n = 3 ± SD. 
 
2.4.3 Peptide Labeling 
In order to investigate the specificity of labeling, sites of labeling were probed using bottom-up 
mass spectrometry. Digestion of native apoMb with trypsin/chymotrypsin produced 36 peptides, of 
which 13 were selected to provide 100 % sequence coverage (Appendix, Fig. A1). Labeled apoMb 
showed ~ 96 % sequence coverage and a maximum of fifteen peptide fragments (obtained with 
20.7 % w/w pLeu) with one, two or four labels (Fig. 2.3). As expected, the signal intensity of labeled 
peptides was less than that of unlabeled peptides, supporting the incomplete labeling observed at 




the labeled and unlabeled peptides obtained after digestion of labeled apoMb differed from those 
in the native protein. This suggests that the label interferes with digestion by obstructing access by 
the enzyme. 
 
Figure 2.3. Digest map of apoMb labeled with 10 mM pLeu. Labeled apoMb was digested with a 
combination of trypsin and chymotrypsin. White bars represent unlabeled peptides, while labeled 
peptides are shown in gray (light gray bars carry one label; dark gray bars carry two labels and the 
black bar carries four labels). Dashed lines represent native peptides. Helical secondary structure 
is represented by cylinders labeled A-E, G and H. Helix F of holomyoglobin (H82-H97) is disordered 
in native apoMb at neutral pH27. 
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As the concentration of pLeu increased, labeling was detected in different regions of the protein 
(Fig. 2.4). Labeling at the peptide level was obtained using MS analysis of digested labeled apoMb 
at various pLeu concentrations (Fig. 2.4(b-h)). At 0 % w/w pLeu, no labeling was observed (Fig. 
2.4b). At 0.3 % w/w pLeu, peptides L32-K42 and T34-K42 were labeled (Fig. 2.4c). This region 
forms helix C and part of helix B. At 1.3 % w/w pLeu, an additional peptide HKIPIKY (H97-Y103; 
located on a loop and part of helix G) was labeled (Fig. 2.4d). As pLeu concentration was increased 
to 2.5 % w/w, labeling was detected in peptide H119-F138 (helix H) in addition to L32-K42, T34-
K42 and H97-Y103 (Fig. 2.4e). At 5 % w/w and 11.6 % w/w pLeu, Y103-K133 was labeled as well 
(Fig. 2.4f, g). At 20.7 % w/w pLeu, label was detected in G1-W14, G1-R31, V17-K42 (helices A, B 
and C), H48-K56 (helix D), H97-K102 (helix G), G124-F138, N140-F151, Y146-G153, E148-F151 
and R139-G153 (helix H), in addition to the previously mentioned sequences (Fig. 2.4h). Increased 
label uptake at the C terminus is consistent with our previous solid-state hydrogen-deuterium 
exchange (ssHDX-MS) results for myoglobin, which showed greater deuterium uptake in this region 
even in the solid state16. Overall, labeling was observed across helices A, B, C, D, G and H. No 
labeling was observed on amino acids A57-K96, which form helices E and F. These two helices 
are involved in heme binding in holomyoglobin (holoMb), but are considerably disordered in 
apoMb27, 28. The absence of label suggests that this region is protected from matrix exposure at the 




Figure 2.4. (a) Ribbon diagram of apoMb showing helices A-E, G and H. (b-h) Ribbon diagram of 
apoMb showing covalent labeling with increasing amounts of pLeu in the matrix in the presence of 
sucrose. (b) 0 (c) 0.3 (d) 1.3 (e) 2.5 (f) 5.0 (g) 11.6 (h) 20.7 %w/w pLeu. (i) Ribbon diagram of 
apoMb showing covalent labeling with 20.7 % w/w pLeu in the presence of Gdn HCl (1.5 M). The 
ribbon diagrams were generated using PyMOL (PyMOL Molecular Graphics System, Version 1.4.1, 
Schrödinger, LLC) and the crystal structure of myoglobin (PDB ID 1WLA; www.rcsb.org). Helix F 
(H82-H97) in the myoglobin structure was modified to an unstructured region, which is observed 





2.4.4 MS/MS Analysis of Peptide L32-K42 (LFTGHPETLEK) 
To obtain additional information on the sites of photolytic labeling, tandem MS analysis was carried 
out on the singly-labeled peptide L32-K42, both in the labeled and native form. After fragmenting 
the native peptide, almost all b- and y-ions were observed (Appendix, Table A1, I and II). However, 
no b-ions were observed in the labeled peptide product ion mass spectrum. Six y-ions (y6, y7, y8, 
y9, y10 and y11) with z = +2 and three y-ions (y4, y5 and y6) with z = +1 were identified by fragmenting 
the labeled peptide at 13 V (Fig. 2.5; Appendix Table A1, III and IV). Unlabeled y-ions (y1-y10) were 
also observed upon fragmentation of the labeled peptide (Appendix, Table A1, III and IV; dotted 
arrows in Fig. 2.5). Assuming that the ionization and fragmentation efficiencies of the labeled and 
native peptides are similar, and that the instrument is sensitive toward all possible labeled and 
unlabeled ions, the results suggest two possible reasons for the differences in fragmentation 
patterns: (1) Labeling is site-specific at Thr (peptide TLEK), since unlabeled y1-y3 and labeled y4-
y11 were observed. The presence of unlabeled y4-y10 could indicate loss of label from Thr during 
fragmentation. (2) Labeling is heterogeneous, with multiple sites of modification ranging from Leu 
to Thr (peptide LFTGHPET), since labeled y4-y11 and unlabeled y1-y10 were observed. The presence 
of unlabeled y1-y10 may be due to neutral loss of label from any of the labeled amino acids in peptide 
LFTGHPET. The absence of b-ions in the product ion spectrum of the labeled peptide makes it 







Figure 2.5. MS/MS spectrum of labeled peptide L32-K42 showing y-ion products obtained by CID 
fragmentation. The asterisk indicates the precursor peptide peak (m/z = 462.91). Dashed arrows 
represent y-ion peaks produced from the labeled peptide and dotted arrows represent y-ion peaks 
produced by possible loss of the label from the corresponding labeled y-ions. Labeled y-ions y11 
(z=+2) and y5 (z=+1) are not shown due to low abundance. 
 
2.4.5 Formulation Effects 
ApoMb lyophilized with Gdn HCl and 100x molar excess of pLeu (~ 1% w/w pLeu) was analyzed 
for label uptake at the peptide level. MS analysis after enzymatic digestion showed that labeling 
occurred at peptides L32-K42, T34-K42 and H119-F138 (Fig. 2.4(i)). This is similar to the labeling 
observed with sucrose at 2.5 % w/w pLeu, but with no labeling on the G helix (at the BG contact 
interface). Gdn HCl is expected to have a chaotropic effect on protein structure and to cause 
increased label uptake due to protein unfolding and higher solvent exposure. In contrast, sucrose 



































is expected to preserve the native structure of the protein through preferential exclusion and show 
lower labeling. These differences between expected and observed labeling patterns may be 
attributed to changes in protein side-chain environment caused by Gdn HCl. 
 
2.4.6 Photolytic Labeling with p-benzoyl-L-phenylalanine (pBpA) 
GCG (1-8)* lyophilized with and without excipients and irradiated in the solid state showed the 
formation of peptide-peptide adducts. Peptide dimers and trimers were observed by ESI-LC-MS; 
these adducts were also present in solution controls. Peptide-excipient adducts were also observed, 
but not for all formulations. Only two formulations (peptide-Met and peptide-Leu) showed peptide-
excipient adducts in both solid and solution, while the sucrose, trehalose and urea formulations 
showed no peptide-excipient adducts in either solid or solution state (Table 2.2). 
 
The first formulation containing GCG (1-8)* and pLeu showed several adducts in the lyophilized 
formulation. Cross-linking occurred between GCG (1-8)* and itself (dimer and trimer) and between 
GCG (1-8)* and pLeu (with and without the loss of N2). The solution control showed GCG (1-8)* 
adducts (dimer and trimer) and GCG (1-8)*-pLeu adducts with the loss of N2. The second 
formulation containing GCG (1-8)*, pLeu and sucrose produced peptide adducts (dimer and trimer), 
peptide-pLeu adducts (with and without the loss of N2), pLeu-sucrose adducts with the loss of N2 
and peptide-pLeu-sucrose adducts with the loss of N2. The solution control showed GCG (1-8)* 






Table 2.2. Cross-linked products formed after irradiation of GCG (1-8)* in various lyophilized 
formulations 
  Cross-linked Products 






GCG (1-8)* + 
Excipient 
Adduct 
GCG (1-8)* alone Solid + + + N/A 
Solution + + + 
N/A 
GCG (1-8)* + 
Sucrosea 
Solid + + + - 
Solution + + + - 
GCG (1-8)* + 
Trehalosea 
Solid + + + - 
Solution + + + - 
GCG (1-8)* + L-
methioninea 
Solid + + + + 
Solution 
+ + + + 
GCG (1-8)* + L-
leucinea 
Solid + + + + 
Solution + + + + 
GCG (1-8)* + 
Ureaa 
Solid + + + - 
Solution 
+ 
+ + - 
Formulation Ab Solid + + + +d,e 
Solution + + + 
+ d 
Formulation Bc Solid + + + + d,e,f,g 







a Excipients were added in a 2:1 w/w ratio with GCG (1-8)*. 
b Formulation A =  GCG (1-8)* and pLeu in a 1:1 molar ratio. 
c Formulation B =  GCG (1-8)*, pLeu and sucrose, with a 1:1 molar ratio of GCG (1-8)* and 
pLeu and 1:2 w/w ratio of GCG (1-8)* and sucrose. 
d GCG (1-8)* + pLeu adduct with loss of N2.  
e GCG (1-8)* + pLeu adduct without loss of N2.  
f pLeu + sucrose adduct with loss of N2.  
g GCG (1-8)* + pLeu + sucrose adduct with loss of N2. 
 
2.4.7 MS/MS Analysis of GCG (1-8)* Monomer and Dimer 
All b-ions (b1-b8; z=+2) and several y-ions were detected after CID fragmentation of GCG (1-8)* 
monomer (data not shown). Fragmentation of the dimer from lyophilized formulations produced 
cross-linked product ions in addition to internal fragment (non-cross-linked) b- and y-ions (Fig. 2.6; 
Appendix Table A2, I and II). In order to assign product ions to cross-linked sequences, the 
nomenclature proposed by Schilling and coworkers was used29. GCG (1-8)* monomer was 
designated as α, while b- and y-ions (from the second monomer unit in the dimer) cross-linked with 
α were designated as b~α- and α~y-ions. The following cross-linked ions were detected: b4~α, b5~α, 
b6~α, b7~α, α~y5 and α~y6. Internal fragment product ions b1, b2, b3, b5, y1, y2, y3 and y4 were also 
detected. The evidence suggests that, for lyophilized GCG (1-8)*, peptide-peptide cross-linking 
occurs preferentially between pBpA and Gly residues. 
 
In solution controls, the fragmentation of the GCG (1-8)* dimer also produced internal fragment 
ions and cross-linked product ions (data not shown). An unambiguous assignment of the site of 





Figure 2.6. MS/MS spectrum of GCG (1-8)* dimer in the lyophilized formulation with L-leucine 
showing b- and y-ion products obtained by CID fragmentation. The asterisk denotes the precursor 
dimer peak (m/z = 646.28). Closed circles represent simple (non-cross-linked) b- and y-ions. Open 
circles represent cross-linked b- and y-ions, labeled as b~α and α~y. Inset shows b- and y-ion 




The studies presented here demonstrate successful photolytic labeling with pLeu and pBpA in 
lyophilized powders. To our knowledge, this is the first reported use of PAAs to study protein-protein 
and protein-matrix interactions in amorphous solids, though previous studies have employed PL-
MS in solutions in liquid and frozen states. For example, PL-MS using pLeu has been reported in 
solution for myoglobin and calmodulin18 using a 1:10,000 molar ratio of protein to pLeu and a pulsed 
laser for irradiation. Calmodulin was detected carrying up to 4 labels, while myoglobin showed up 
to 2 labels. Our studies with apoMb were unable to detect covalent labeling in solution at a 1000x 
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molar excess of pLeu. This may be due to differences in irradiation energy in the two studies. 
However, solid state labeling with 100x molar excess of pLeu showed up to 6 labeled populations 
in our studies, suggesting that labeling with pLeu is more efficient in the solid state than in solution, 
perhaps due to greater proximity of protein and pLeu, low water content and/or reduced mobility in 
the solid state.  
 
PL-MS with pLeu has also been used previously to study the effect of carbene diffusion and solvent 
accessibility in frozen calmodulin solutions30. In frozen solutions, Jumper et al observed labeling at 
multiple sites, with higher labeling yields at Glu and Asp and no correlation with solvent accessibility. 
They proposed that pre-concentration of pLeu at the protein surface prior to freezing (driven by 
electrostatic interaction) and carbene diffusion (driven by temperature) dictated preferential labeling 
at carboxylate groups. In our studies in lyophilized solids, site-specific labeling such as this was not 
detected, though we were able to localize the label to the peptide level. Jumper et al used high-
energy collisional dissociation (HCD) and electron-transfer dissociation (ETD), rather than the CID 
fragmentation used here. It is possible that CID fragmentation may have caused some loss of label, 
as has been reported previously30, 31. Alternatively, there could be multiple sites of labeling in the 
lyophilized samples, as expected given the non-specific nature of carbene reactivity. Kolbel and 
coworkers observed multiple cross-links between pLeu and Gly, Leu and Tyr when pLeu was 
incorporated within a peptide sequence and irradiated in solution19. Their results indicated 
preferential labeling based on secondary structural constraints, rather than chemical reactivity.  
 
Though our results do not support preferential labeling of specific functional groups, preferential 
labeling was observed at the peptide level in lyophilized samples, which varied with the pLeu 
content of the solid (Fig. 2.4 (b-h)). Interestingly, the peptides labeled preferentially (i.e., labeled at 
the lowest pLeu concentrations and at higher concentrations) correspond to those in the molten 
globule of apoMb in solution. In solution, apoMb has molten globule characteristics at neutral pH, 




→ ABGH → ABCDEGH33. Interactions between the BG helix pair are critical in maintaining the 
stability of the AGH core and promoting favorable interactions between the GH helix pair34, 35. BG 
and GH interactions cause the largest decrease in solvent accessible surface area upon folding36. 
These interactions are also thought to destabilize helices E and F, which are less stable than 
helices A, B, G and H35, 37. Our ssPL-MS data showed that helices B, G and H are among the first 
to be labeled at lower pLeu concentrations, while helices E and F show no label uptake even at 
pLeu higher concentrations.  This suggests that the molten globule is intact in lyophilized solids 
and is preferentially labeled, perhaps because amino acid side chains are exposed to pLeu in the 
matrix when the helices are intact. Interaction of pLeu with these regions prior to lyophilization 
cannot be ruled out, however.   
 
ssPL-MS was also used to examine formulation effects on the side-chain environment, with peptide 
level resolution.  In the presence of sucrose and 100x molar excess of pLeu (20.7 % w/w pLeu), 
apoMb showed labeling on all helices except E and F. When Gdn HCl was included as an excipient, 
CD spectroscopy of the solution prior to lyophilization showed loss of signal at 222 nm and 208 nm 
(data not shown), confirming that the protein had lost helicity. We expected that the Gdn HCl 
unfolded protein would remain unfolded after lyophilization and would be labeled to a greater extent 
than folded protein (e.g., in sucrose, as in our previous ssHDX studies17, 38). Instead, photolytic 
labeling was less in solids containing Gdn HCl than in those containing sucrose. This may be due 
in part to the high mass fraction of Gdn HCl in the lyophilized solid (~0.97), limiting interaction 
between the protein and pLeu by simple dilution. The high Gdn HCl fraction in the solid is the result 
of the high molar concentration used to unfold apoMb in solution, and is greater than the mass 
fraction of sucrose (~0.50) in the sucrose formulation. Preferential interaction of guanidinium ions 
with apoMb may also contribute, blocking protein-pLeu interactions and thereby inhibiting pLeu 
labeling39. Similarly, the high ionic strength of the Gdn HCl solutions prior to lyophilization may 





To complement studies with pLeu incorporated into the matrix as an excipient, studies were also 
performed with a PAA incorporated into the peptide sequence.  This approach has been used to 
map the interactome in cells and to study PPIs in vitro21, 40, 41. The studies used an octapeptide 
derived from the N-terminal sequence of glucagon (GCG (1-8)*), with pBpA at the F6 position. 
Glucagon is a 29 amino-acid peptide used to treat insulin-induced hypoglycemia. The monomeric 
peptide is relatively unstructured in solution, but forms fibrils in acidic and alkaline pH42-44. Previous 
experimental and computational reports have assigned higher aggregation tendency to glucagon’s 
N- and C-termini44-46. For example, Pedersen et al used experimental Ala mutation to study 
glucagon aggregation in solution and observed that mutations at residues F6, Y10, V23 and M27 
decreased the rate of fibrillation at acidic pH44. Their results indicated that regions 6-10 and 23-27 
are involved in fibrillation. Solution-state HDX-NMR studies have also indicated involvement of the 
N-terminus in aggregation45.  
 
We used GCG (1-8)* to study peptide-peptide and peptide-matrix interactions of the N-terminal 
sequence in solution and in the solid state, in the presence of various excipients. In solid samples, 
adducts of pBpA with L-Met and L-Leu excipients were observed. Adducts were not detected in 
lyophilized solids containing sucrose, trehalose or urea. The formation of adducts with L-Met and 
L-Leu may be attributable to their free, electron-rich C-H groups, which are known to react with the 
ketyl radical of pBpA26, 47. Preferential exclusion of sucrose and trehalose from the vicinity of the 
peptide in the pre-lyophilized solution48, 49 may contribute to the lack of adduct formation with these 
excipients. Urea was selected as a negative control, since it has no C-H groups and hence is not 
expected to form adducts with pBpA, as was observed. In addition to protein-matrix interactions, 
studies with GCG (1-8)* were able to capture PPIs at the interface of dimers in the solid state, with 
amino acid-level resolution. The studies showed that the pBpA label interacts preferentially with G6 
in forming the dimer (Fig. 2.6).  In contrast, there appear to be multiple cross-linking sites in solution, 
perhaps due to greater mobility of the peptide in solution and/or multiple alignments of two 




Formulations containing both GCG (1-8)* and pLeu, with and without sucrose, were used to 
examine interactions in the solid state and in solution. In these studies, photolytic labels are present 
in both the peptide sequence and in the matrix. Following photoirradiation, peptide dimers and 
trimers, binary adducts of GCG (1-8)* with pLeu, binary adducts of pLeu with sucrose, and ternary 
adducts containing GCG (1-8)*, pLeu and sucrose were detected (Table 2.2). The two PAAs (i.e., 
pLeu, pBpA) are activated at the same wavelength, but have different mechanisms of labeling. The 
formation of a peptide-pLeu complex with the loss of N2 is consistent with the mechanism of 
carbene labeling through pLeu activation, while adducts formed without the loss of N2 are consistent 
with labeling through pBpA activation. In solids containing binary mixtures of GCG (1-8)* and pLeu, 
both types of adducts were detected, indicating activation and labeling via both pLeu and pBpA 
(Formulation A, Table 2.2). In solution, products were detected only with loss of N2 indicating adduct 
formation via pLeu and not via pBpA, perhaps due to reaction of activated pBpA with water.  In 
solids containing GCG (1-8)*, pLeu and sucrose (Formulation B, Table 2.2), ternary adducts were 
detected with the loss of N2, indicating participation of both PAAs in the formation of the adduct. It 
is unlikely that GCG (1-8)* interacts with sucrose directly in these ternary adducts, since it did not 
form adducts with sucrose in the binary formulation. Together, these studies with samples 
containing both GCG (1-8)* and pLeu show that peptide-peptide and peptide-matrix interactions 
can be detected, and that reactivity of the two PAAs differs in solution and in the solid state. 
 
The irreversible nature of photolytic labeling and complementarity to ssHDX-MS makes ssPL-MS 
a useful tool to study the protein environment in lyophilized powders. The primary advantage of 
using a PAA in the excipient matrix is the ease of labeling; the PAA simply needs to be added in 
an appropriate concentration to the pre-lyophilized solution. Moreover, since the PAA is only 
activated at a certain wavelength range and has a very short lifetime (nanosecond scale for singlet 
state carbene in solution, 80-120 μs for ketyl radicals in the triplet state in solution26, 50), the 
photolabeling reaction can be better controlled than with other labeling reagents such as sulfo-N-




reagent. Another benefit of the non-specific diazirine chemistry is that the entire protein structure 
can be probed, as opposed to reagents such as NHSA and 2,3- butanedione that target only lysine, 
N-terminal amino acids and arginine. However, non-specific labeling with diazirine-based probes 
poses analytical challenges. Our results showed that ssPL-MS with apoMb and pLeu could identify 
the location of the label at the peptide level, but MS/MS using CID failed to provide amino acid-
level resolution. Labeling with PAAs incorporated in the protein sequence overcomes this hurdle 
by localizing the site of labeling to particular amino acid(s), with the attendant disadvantage that 
the PAA-labeled peptide/protein must first be synthesized. Incorporating the label in the protein 
sequence provided residue-level information about the sites of interaction, as shown with GCG (1-
8)*.  
 
The results have implications for formulation design and stability testing in the biopharmaceutical 
industry. The high resolution of ssPL-MS can facilitate rational design of formulations by allowing 
excipients to be selected and created based on their interactions with the protein side-chain. The 
information can also be used to improve protein drugs themselves through protein engineering. 
Ongoing work in our laboratory is developing alternate approaches to incorporate photolytic label 
into the protein sequence, including the use of auxotrophic cell lines and site-directed mutagenesis 
51, 52. The use of heterobifunctional cross-linkers such as succinimidyl 4,4’- azipentanoate, which 
contains a primary amine-specific NHS functional group and a non-specific diazirine functional 
group, is also being explored as an alternative approach to label incorporation. 
 
2.6 CONCLUSIONS 
Peptide-level information about protein structure and environment in lyophilized formulations was 
obtained using ssPL-MS. Photoactive probes can be used externally in the matrix or incorporated 
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CHAPTER 3. PHOTOLYTIC CROSSLINKING TO PROBE MOLECULAR INTERACTIONS IN 
LYOPHILIZED SOLIDS 
This chapter was published as a research article in Molecular Pharmaceutics (2013) and can be 
found online at http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00183 
 
3.1 ABSTRACT 
Protein structure and local environment in lyophilized formulations were probed using high-
resolution solid-state photolytic crosslinking with mass spectrometric analysis (ssPC-MS). In order 
to characterize structure and microenvironment, protein-protein, protein-excipient and protein-
water interactions in lyophilized powders were identified. Myoglobin (Mb) was derivatized in solution 
with the heterobifunctional probe succinimidyl 4,4’-azipentanoate (SDA), and the structural integrity 
of the labeled protein (Mb-SDA) confirmed using CD spectroscopy and liquid chromatography / 
mass spectrometry (LC-MS). Mb-SDA was then formulated with and without excipients (raffinose, 
guanidine hydrochloride (Gdn HCl)) and lyophilized. The freeze-dried powder was irradiated with 
ultraviolet light at 365 nm for 30 min to produce crosslinked adducts that were analyzed at the intact 
protein level and after trypsin digestion. SDA-labeling produced Mb carrying up to 5 labels, as 
detected by LC-MS. Following lyophilization and irradiation, crosslinked peptide-peptide, peptide-
water and peptide-raffinose adducts were detected. The exposure of Mb side chains to the matrix 
was quantified based on the number of different peptide-peptide, peptide-water and peptide-
excipient adducts detected. In the absence of excipients, peptide-peptide adducts involving the CD, 
DE and EF loops and helix H were common. In the raffinose formulation, peptide-peptide adducts 
were more distributed throughout the molecule.  The Gdn HCl formulation showed more protein-
protein and protein-water adducts than the other formulations, consistent with protein unfolding and 








Protein drugs are the fastest growing sector of the pharmaceutical industry, a trend likely to 
continue given multiple impending patent expirations and a crowded biosimilars pipeline 1. A 
distinguishing feature of protein drugs is the relationship between conformation, dynamics and 
biological function. The three-dimensional structure of proteins is the result of hydrophobic, 
covalent and electrostatic interactions and hydrogen bonding, and can be disrupted during 
manufacture, formulation and storage. It is generally accepted that maintaining a near-native- 
conformation in the formulation is essential for both efficacy and safety. Misfolded or partially 
unfolded species are often more prone to degradation and/or aggregation, complicating 
manufacturing and increasing the potential for adverse immunogenic reactions in patients. With the 
emergence of biosimilars, extensive characterization of protein structure is required to demonstrate 
that the product is “highly similar” to the reference product; hence, it is even more essential to 
reliably characterize protein structure in both solid and solution formulations with sufficient 
resolution.  
 
Though proteins are often lyophilized to preserve structure during API storage and/or in the final 
formulation, degradation and aggregation can occur during the freeze-drying process, storage and 
reconstitution 2-4. Stabilizers such as disaccharides offer some protection, but are not always 
effective. As a result, formulation is often a largely trial-and-error process, and can be time-
consuming and expensive. Moreover, the structure of proteins in lyophilized solids is not well 
studied by conventional techniques, further hindering the formulation process.  
 
Lyophilization typically produces an amorphous solid powder, unless crystallizing excipients such 




trehalose have demonstrated the ability to retain native protein structure and activity 5-7. Two 
hypotheses have been proposed to explain this stabilization: (1) the water replacement theory, 
which asserts that carbohydrates substitute for water and form hydrogen bonds with the protein 
and (2) the vitrification theory, which claims that the formation of a glassy solid reduces protein 
mobility and so preserves structure and stability. While support for each of these hypotheses has 
been presented by a number of groups, to date it has not been possible to probe protein-water 
interactions in amorphous solids directly, and so only indirect evidence regarding water 
replacement has been available 8-10. To understand the interactions that control protein 
conformation and stability in amorphous solids, a method to directly detect both protein-matrix and 
protein-water interactions in lyophilized solids is needed. 
 
Current methods used to characterize protein structure in lyophilized solids cannot detect these 
interactions and lack structural resolution. For example, differential scanning calorimetry (DSC) is 
used to study the thermal stability of lyophilized protein formulations based on the glass transition 
temperature (Tg), while Fourier-transform infrared (FTIR) spectroscopy has been used to determine 
protein secondary structure. Although these methods are used to compare formulations, their low-
resolution and lack of detailed structural information are inherent limitations. Moreover, Tg is a bulk 
measure and does not always correlate with protein stability, since degradation mediated by local 
fluctuations and residual water can occur at temperatures below Tg 11, 12. High-resolution methods 
such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography are not 
generally applicable to amorphous samples, since they require large amounts of sample with some 
long-range order and/or isotopic labeling.  In addition, FTIR and NMR generate ensemble-averaged 
spectra that usually cannot distinguish sub-populations containing different protein conformers. 
Thermogravimetric analysis (TGA) and Karl-Fischer titration have been used to determine the bulk 
water content of the formulation, but cannot identify the local distribution of hydration within a 





To provide higher resolution structural information on proteins in lyophilized solids, our group has 
developed solid-state hydrogen deuterium exchange with mass spectrometric analysis  (ssHDX-
MS) and applied it successfully to analyze protein conformation in lyophilized powders, achieving 
peptide-level resolution. ssHDX-MS is able to distinguish the effects of different formulation 
excipients on structure in lyophilized solids 13, 14, and, in a recent study of lyophilized myoglobin 
formulations, provided significantly higher correlation with aggregation during storage than FTIR 15.  
ssHDX-MS is not without its limitations, however. As in solution HDX, loss of the deuterium label 
due to back-exchange occurs rapidly for side-chain functional groups, so that only the exposure of 
the peptide backbone can be probed. Back exchange also necessitates rapid analysis of 
deuterated samples.  
 
To address these limitations, we have developed a complementary approach to ssHDX-MS called 
solid-state photolytic labeling- mass spectrometry (ssPL-MS) 16. This method utilizes a photoactive 
reagent such as photo-leucine (pLeu; L-2-amino-4, 4'-azipentanoic acid) as an excipient and an 
external probe. UV irradiation of the freeze-dried solid activates the probe, leading to covalent 
labeling of matrix-accessible protein side-chains. Unlike ssHDX-MS, there are no constraints with 
respect to experimental conditions (pH, temperature) as the pLeu label is stable and does not 
undergo back-exchange. Using this method, we studied excipient effects on protein side-chain 
environment with peptide-level resolution16.  
 
Building on those findings, the studies reported here present a new approach to interrogating 
protein interactions in amorphous solids based on photolytic crosslinking. Photolytic crosslinking 
has been widely used in molecular biology to study protein-protein interactions in living cells 17-19, 
and is adapted here to a condensed phase. In this approach, termed solid-state photolytic cross-
linking with mass spectrometric analysis (ssPC-MS), a heterobifunctional crosslinking reagent (e.g. 
succinimidyl 4, 4’- azipentanoate; SDA) is first used to derivatize reactive side chains in the protein 




a certain wavelength, a covalent bond is created between the derivatized side chain and another 
nearby molecule in the solid matrix.  After reconstitution, the crosslinked protein is analyzed by LC-
MS at the intact level, or digested enzymatically prior to LC-MS analysis to assess the number and 
type of adducts formed and to identify the different interactions experienced by particular proteolytic 
fragments. Alternatively, the reactive side chain may be engineered into the protein sequence, e.g., 
using photoactive amino acid derivatives such as pLeu.  The length of the crosslinker can be varied 
by changing the length of the spacer arm, allowing the environment at different distances from the 
protein side chain to be probed.  
 
ssPC-MS is similar to ssPL-MS in that both use photolytic reactions and hence are amenable to 
the solid state, in contrast to solution-state labeling reagents that are pH-sensitive. In ssPL-MS, the 
photoactive functional group is part of an excipient in the solid matrix, while in ssPC-MS the 
photoreactive functional group is incorporated onto protein side chains (Appendix, Fig. A3). ssPL-
MS reactions are carried out in a single step while crosslinking with a heterobifunctional reagent 
requires two-step activation. Matrix-accessible side-chains are derivatized by covalent labeling, 
whereas crosslinking results in covalent linking of a side-chain with any matrix component such as 
protein, water or excipient. Thus labeling provides information about structural changes and matrix 
accessibility at the side-chain level whereas crosslinking advances this method by providing direct 
information about the microenvironment of a side-chain. The labeling reagent photo-leucine and 
the crosslinker SDA both contain a photoactive diazirine ring that is activated at 350-365 nm and 
forms a reactive singlet carbene (Appendix, Fig. A1). The carbene can undergo internal conversion, 
insert into any X-H bond (X= C, O, N, S) or add on to a C=C bond, forming covalent adducts with 
species within the distance of the spacer arm, including water, formulation additives (e.g. raffinose) 
and other protein molecules 20. ssPC-MS and ssPL-MS are similar to ssHDX-MS in that all three 
techniques label the protein and reflect protein conformation in the solid state. The methods differ 
in that ssPC-MS and ssPL-MS map the interactions of protein side-chains with the surrounding 




the labeling reactions of ssPC-MS and ssPL-MS are irreversible and so are not subject to the back-
exchange that occurs in ssHDX-MS and other hydrogen-deuterium exchange methods. 
 
To evaluate the utility of ssPC-MS, we used the heterobifunctional crosslinker SDA (spacer arm 
length 3.9 Å) to derivatize equine myoglobin (Mb) in various formulations. Crosslinking with SDA is 
a two-step process. In the first step, a succinimidyl ester is activated in solution at pH 6-9 and reacts 
with available primary amines in the protein, usually Lys side chains and the N-terminus. Following 
lyophilization, the photoactive diazirine group of SDA is activated by exposing the solid powder to 
UV-A light at 365 nm, resulting in the loss of N2 and the formation of a reactive carbene. The 
carbene inserts into any X-H bond (X= C, O, N, S) or adds on to a C=C bond, forming covalent 
adducts with species within the distance of the spacer arm, including water, formulation additives 
(e.g. raffinose) and other protein molecules.  Based on the number of peptide-peptide, peptide-
water and peptide-excipient adducts, the microenvironment of derivatized protein side chains was 
characterized with high resolution. Importantly, SDA labeling and ssPC-MS provided direct 
evidence for the perturbation of protein structure in the solid state and provided support for regional 
water-replacement in lyophilized protein-carbohydrate systems. 
 
3.3 MATERIALS AND METHODS 
Holo-myoglobin from equine skeletal muscle (Mb), potassium phosphate monobasic and dibasic, 
Tris base, D-(+)-raffinose pentahydrate, guanidine hydrochloride (Gdn) and anhydrous dimethyl 
sulfoxide (DMSO) were purchased from Sigma Aldrich (St. Louis, MO). The heterobifunctional 
crosslinker succinimidyl 4,4'-azipentanoate (SDA) was obtained from Thermo Scientific (Rockford, 
IL). Trypsin was obtained from Promega (Madison, WI) and mass spectrometry-grade water, 





3.3.1 Sample Preparation 
Mb was dissolved in potassium phosphate buffer (2.5 mM, pH 7.4) and dialyzed using cellulose 
ester tubing (MWCO 8-10 kDa, Spectrum Laboratories, Rancho Dominguez, CA) against the same 
buffer for 24 h. The dialyzed protein stock solution was filtered through a 0.22 µm syringe filter 
(Gelman Nylon Acrodisc 13) and the protein concentration measured by visible spectroscopy 
(extinction coefficient ε555nm = 12.92 mM-1cm-1). This stock solution was used for further experiments. 
Stock solutions for raffinose and Gdn (3 M) in potassium phosphate buffer (2.5 mM, pH 7.4) were 
prepared, filtered through a 0.22 µm syringe filter and stored at 4 °C until use. A 10 mM stock 
solution of SDA in DMSO was prepared and stored away from light at room temperature. 
 
3.3.2 Labeling Mb with SDA in Solution 
To covalently link the SDA label to Mb via the NHS group, stock solutions of Mb and SDA were 
mixed such that the protein: SDA molar ratio was 1:10 (final SDA concentration 0.39 mM). The 
mixture was allowed to stand at room temperature in the dark for 15 min followed by quenching 
with Tris HCl (100 mM final concentration, pH 8.0). The labeled protein sample (hereinafter referred 
to as Mb-SDA) was desalted using a spin desalting column (MWCO 7 kDa; Thermo Scientific, 
Rockford, IL) to remove excess unreacted SDA. The desalted Mb-SDA solution was stored at 4 °C 
and used for crosslinking experiments. 
 
3.3.3 Structural Integrity of Labeled Protein 
Far-UV CD spectroscopy was used to determine the effect of SDA labeling on protein secondary 
structure. Unlabeled and SDA-labeled Mb samples (Mb labeled with 10x molar excess of SDA; 
0.39 mM SDA) were diluted to 3.6 µM and molar ellipticity measured on a JASCO J-815 
spectrometer (JASCO Analytical Instruments, Easton, MD) in a 0.1 cm path length quartz cuvette. 
Spectra were acquired from 180 nm to 260 nm at a scanning speed of 50 nm/min. Structural 
integrity was also monitored by measuring the extent of protein modification as a function of SDA 




and 1.02 mM) for 15 min. The reaction was quenched with Tris HCl as above and the samples 
diluted to 20 pmol protein for LC-MS analysis. The fraction of each labeled species was calculated 
from the respective peak heights in the extracted ion chromatogram (EIC): 
 
FL, i =  
(Peak height)L, i 
∑ (Peak height)L,i10𝑖𝑖=0
                                                                                                  Equation 3.1 
 
where FL, i is the fraction of protein containing i SDA labels (i = 0,1,…,10), the numerator is the peak 
height for protein containing i SDA labels and the denominator is the sum of peak heights for 
unlabeled protein (protein remaining unlabeled after quenching the labeling reaction; i = 0) and 
labeled protein (i = 2,…,10). The concentrations of each labeled species (PL, i) were calculated by 
multiplying FL, i by the initial protein concentration (P0).  
 
PL, i = P0FL, i                                                                                                                                                                                Equation 3.2 
 
The concentrations of unlabeled protein (P) and unused SDA remaining after quenching the 
labeling reaction (X) were calculated as follows: 
 
P = P0FL, i=0                                                                                                                   Equation 3.3  
 
𝑋𝑋 = X0 −  ∑ 𝑖𝑖PL, i10𝑖𝑖=1                                                                                                         Equation 3.4 
 
where P0 is the initial protein concentration and X0 is the initial SDA concentration. To test whether 
the labeling reaction is second order, the natural logarithm of the ratio (PX0/P0X) was plotted against 





3.3.4 Lyophilization and Crosslinking in the Solid State 
Stock solutions of Mb-SDA and raffinose were mixed such that the protein: raffinose ratio was 1:3 
w/w (Table 3.1). A second formulation containing Mb-SDA and Gdn was prepared with a final 
concentration of 1.5 M Gdn (Table 3.1). The formulations were lyophilized as described previously16. 
Briefly, samples were lyophilized in borosilicate clear glass vials according to the following cycle: 
loading samples on shelves precooled to -2 °C, freezing at -40 °C for 50 min (shelves precooled to 
-2 °C), followed by drying under vacuum (70 mTorr) over 5 steps (-35 °C for 10 h, -20 °C for 8 h, -
5 °C for 6 h, 10 °C for 6 h and 25 °C for 6 h). Lyophilized samples were stored at -20 °C until use. 
Unlabeled Mb (Mb without SDA labeling) and Mb-SDA were formulated and lyophilized separately 
and used as controls. 
 
Table 3.1. Composition of lyophilized formulations. 
Lyophilized Formulation 
% w/w 
Mb a SDAa Buffer Excipient 
Mb-SDA (10x) b 60.6 0.7 38.7 N/A 
Mb-SDA (10x) + Raffinose (1:3 w/w) 21.5 0.2 13.7 64.5 
Mb-SDA (10x) + Gdn a (1.5 M) 0.18 0.03 0.27 99.53 
 
a Mb, myoglobin; Gdn, guanidine hydrochloride; SDA, succinimidyl 4,4'-azipentanoate. 
b Mb-SDA (10x) denotes Mb labeled with 10x molar excess of SDA in solution. 
 
The samples were tested for SDA-labeling-induced structural perturbations of Mb secondary 
structure in lyophilized powders. Solid-state Fourier transform infrared (ssFTIR) spectroscopy was 
carried out for the unlabeled and SDA-labeled samples using a Tensor 37 spectrometer (Bruker 
Optics, Billerica, MA) as described previously13. The moisture content of the SDA-labeled Mb 
formulations was determined using a gravimetric analyzer (Q5000SA; TA Instruments, New Castle, 




lyophilized powder was loaded onto the platinum sample pan and exposed at 50 ˚C, 0 % RH for 2 
h, with data acquisition at 4 s intervals.  
 
Crosslinking was initiated by irradiating the freeze-dried samples at 365 nm for 30 min using a UV 
Stratalinker 2400 (Stratagene Corp., La Jolla, CA) as described previously16. The irradiated 
samples were reconstituted in 200 µL ammonium bicarbonate (100 mM, pH 8.0) and stored at 4 °C 
until further use. For intact protein analysis using LC-MS, the reconstituted samples were diluted 
to 20 pmol protein with MS water containing 0.1 % formic acid. 
 
3.3.5 Digestion of Crosslinked Protein 
Mb-SDA crosslinked in the presence or absence of excipients in the solid state was reconstituted 
with 200 µL ammonium bicarbonate (100 mM, pH 8.0) and digested with trypsin (1:10 molar ratio 
of trypsin to protein) at 60 °C for 16 h, then quenched with MS water containing 0.1 % formic acid. 
Solution controls were prepared for all three formulations and were digested similarly after 
crosslinking in solution. 
 
3.3.6 Mass Spectrometry 
Labeled and crosslinked solid- and solution-state samples were analyzed using an HPLC-MS 
system equipped with an ESI source (1200 series HPLC, 6520 qTOF; Agilent Technologies, Santa 
Clara, CA). Tryptic peptides (SDA-labeled and unlabeled) and peptide adducts were separated on 
a ZORBAX SB-C18 column (Agilent Technologies; 1.0 x 50 mm, particle size 3.5 µm) using a 
gradient, as described previously16. MS/MS was performed on selected peptides labeled with SDA 
(Appendix, Table A3). The peptides were fragmented using CID (13 V) and the product ions 





3.3.7 Data Analysis 
The software package GPMAW (Version 9.21b3, Lighthouse Data, Odense, Denmark) was used 
to generate a list of theoretical masses for peptide-peptide adducts. Information regarding the 
protein (amino acid sequence from UniProtKB P68082), enzyme (trypsin; up to 4 missed cleavages) 
and crosslinker SDA (heterobifunctional; MW of the crosslinking spacer arm (C5H6O) 82.042 Da, 
amine to carboxylic acid specificity) was created in the software. Two other lists were prepared 
manually for peptide-raffinose and peptide-water adducts. Up to four missed cleavages with trypsin 
and up to four SDA labels per peptide (with up to four raffinose or water adducts, correspondingly) 
were considered, along with dead-end modifications (SDA-N2), in which N2 is lost without the 
formation of an adduct. The theoretical masses were compared with observed masses using 
MassHunter software (Agilent Technologies, Santa Clara, CA) to detect peptide-peptide, peptide-
excipient and peptide-water adducts. To compare excipient effects quantitatively, peptide-peptide, 
peptide-water and peptide-excipient adducts were counted for each formulation. Local changes in 
protein-matrix interactions were quantified by calculating peptide ‘crosslinking numbers’, described 
in detail below. 
 
3.3.7.1 Data Analysis for Crosslinking Numbers (X1n) 
45 overlapping peptides were found to be involved in peptide-peptide adducts (refer below, section 
‘Data Analysis for Qualitative Matrices). To compare local excipient effects quantitatively, 
overlapping peptides were assigned to 8 groups, roughly corresponding to their position in the 
amino acid sequence (Table 3.2). The peptide-peptide adducts obtained for peptides in each group 
were counted and summed together to obtain a ‘crosslinking number’ for that group. The identity 
of the crosslinking partner peptide was not considered; instead all partner peptides obtained after 
crosslinking were considered in counting the number of adducts. Statistical analyses were 
performed using OriginPro (Version 8.6, OriginLab, Northampton, MA) to compare crosslinking 




formulations. Crosslinking numbers were also obtained for peptide-water and peptide-excipient 
adducts for all 8 groups and compared statistically. 
 
The number of SDA labels varied from 1 to 4 for tryptic peptides (see Results). This may give rise 
to artifacts in crosslinking numbers, since peptides carrying more SDA labels are expected to 
crosslink with multiple partners, giving artificially high crosslinking numbers for some groups. To 
avoid this bias, crosslinking numbers for each group were normalized by dividing by the average 
number of SDA labels (n) in the group (Table 3.2), calculated as follows: 
 
𝑛𝑛 =  
[(1)(number of peptides with 1 SDA)  + (2)(number of peptides with 2 SDA)
 + (3)(number of peptides with 3 SDA) +  (4)(number of peptides with 4 SDA)]
(Total number of labeled peptides (with 1 − 4 SDA) in the group)
 
 
A second bias may arise due to the number of tryptic peptides in each group. Groups with more 
peptides will generate larger crosslinking numbers, as the crosslinking number is a sum of the 
number of adducts obtained for all peptides within a group. For example, Group 1 has 1 tryptic 
peptide while Group 4 has 15 peptides (Table 3.2). Hence a larger crosslinking number for Group 
4 may not necessarily reflect more interactions, but may simply be a result of the number of 
peptides within the group. Crosslinking numbers were therefore normalized a second time by 
dividing by the number of tryptic peptides in each group (Table 3.2). 
 
The “peptide crosslinking number” is defined as the number of chemically distinct adducts detected 
between that peptide and another peptide fragment, water and/or raffinose. Peptide crosslinking 
numbers are specific to a particular peptide fragment and do not represent the total number of 
adducts in the protein as a whole. For a particular group (Table 3.2), the number of unique adducts 
detected (i.e. sum of peptide crosslinking numbers for all peptides included within the group) is 
summarized in the “group crosslinking number”, X1n. Here, the subscripts n=1, 2, 3 indicate peptide-




crosslinked by up to 4 SDA labels are included, as described above. The parameter X11 
encompasses all peptide-peptide adducts formed for peptides within a group without regard to the 
identity of the binding partner.  For example, the following crosslinked peptide-peptide adducts were 
detected for Group (3) (Table 3.2) in the absence of excipients: (Leu32-Lys45) x (Lys63-Lys77), (Leu32-
Lys47) x (Ala57-Lys62) and (Leu32-Lys47) x (Ala57-Lys63). Hence the peptide-peptide crosslinking 
number (X11) for Group (3) is 3. This group also formed the following peptide-water adducts in the 
absence of excipients: Leu32-Lys47 + 3SDA + 2H2O and Leu32-Lys45 + 4SDA + H2O (NB: The 
reaction of diazirine with water occurs with loss of nitrogen (-N2) and may or may not include dead-
end modifications, so product masses are reduced accordingly). Hence the peptide-water 
crosslinking number (X12) for Group (3) is 2. X1n values were normalized by dividing by the average 
number of SDA labels in each group and by the number of tryptic peptides in each group, as 





















1 1-16 1 1 Gly1-Lys16 N-terminus, Helix A 
2 17-31 2.5 1 Val17-Arg31 AB loop, Helix B 




Helix B, BC loop, 
Helix C, CD loop 
















CD loop, Helix D, 






Table 3.2. Classification of peptides based on trypsin digestion pattern (continued). 




Helix E, EF loop 









Helix E, EF loop, 
Helix F, FG loop 





FG loop, Helix G 

















a Average number of SDA labels per group (n) was calculated as described in Materials and 
Methods. 
 
3.3.7.2 Data Analysis for Qualitative Matrices 
At the Mb-SDA digest level, 100 non-redundant overlapping peptides labeled with 0-4 labels were 
detected (72 labeled and 28 unlabeled). Due to matrix heterogeneity arising from variable SDA-
labeled populations, promiscuity of the reactive carbene and the amorphous nature of lyophilized 
solids, considering only non-overlapping peptides may result in loss of information regarding the 
adducts present. Hence, all overlapping peptides were included in the analysis. Since the 
crosslinked species differ in abundance and ionization efficiencies, and since authentic standards 
of the more than 100 crosslinked species produced were not available, the crosslinked adducts 
formed in the solid state were not quantified. Instead, a qualitative approach was used to describe 
the detectable interactions of the protein in lyophilized formulations. Theoretically, each of the 72 
labeled peptides can crosslink with any of the 100 non-redundant overlapping peptides upon 
irradiation. Additional combinations are possible due to multiple dead-end modifications, and a 
crosslinked adduct may contain more than 2 peptides if they are crosslinked by more than one SDA 
molecule. The list for all such possible combinations is > 2.2 x 107 compounds. For simplicity, only 
those adducts consisting of 2 peptides linked by 1 to 4 SDA were considered. For all three 
formulations, 69-80 % of the peptide-peptide interactions involved crosslinking through 1 SDA, with 
fewer adducts detected containing ≥ 2 SDA molecules. 45 overlapping tryptic peptides were found 
to be involved in such peptide-peptide adducts and 44 overlapping tryptic peptides labeled with 1 
to 4 SDA molecules were found to interact with water and raffinose and were selected for the matrix 
(Fig. 4 and 5). 
 
Peptide-peptide interactions for each formulation were mapped qualitatively as a symmetric matrix 
showing the interactions detected in three replicate LC-MS injections (main text, Fig. 4). In the map, 




detected. An interaction was considered “detected” if one or more masses corresponding to the 2 
peptides linked by 1 to 4 SDA was observed. Adducts detected in a single injection represent 
crosslinking between multiple pairs of proteins. Repeat injections of the same sample did not 
always give the same adducts, perhaps due to matrix heterogeneity, variable number of SDA labels 
and/or low concentration of crosslinked species (Appendix, Fig. A7). For example, for Mb-SDA 
crosslinked in the absence of excipients, the first injection produced 41 total peptide-peptide 
adducts (including 16 adducts absent in the second and third injections), the second injection 
produced 40 adducts (including 11 adducts absent in the first and third injections) while the third 
injection produced 37 adducts (including 6 adducts absent in the first and second injections). An 
average of 54-67 % of the adducts were observed in all three injections for all formulations. Similar 
maps showing the maximum number of SDA linkages (1, 2, 3 or 4), maximum number of water 
molecules (1, 2, 3 or 4) and maximum number of raffinose molecules (1) in each adduct after a 
single injection are provided in SI (Appendix, Fig. A5 and A6). 
 
45 overlapping peptides were found to be involved in peptide-peptide adducts (see Results). To 
compare local excipient effects quantitatively, overlapping peptides were assigned to 8 groups, 
roughly corresponding to their position in the amino acid sequence (Table 3.2). The peptide-peptide 
adducts obtained for peptides in each group were counted and summed together to obtain a 
‘crosslinking number’ for that group. The identity of the crosslinking partner peptide was not 
considered; instead all partner peptides obtained after crosslinking were considered in counting the 
number of adducts. Statistical analyses were performed using OriginPro (Version 8.6, OriginLab, 
Northampton, MA) to compare crosslinking numbers (1) between groups within the same 
formulation and (2) for the same group across formulations. Crosslinking numbers were also 
obtained for peptide-water and peptide-excipient adducts for all 8 groups and compared statistically. 
 
The number of SDA labels varied from 1 to 4 for tryptic peptides (see Results). This may give rise 




crosslink with multiple partners, giving artificially high crosslinking numbers for some groups. To 
avoid this bias, crosslinking numbers for each group were normalized by dividing by the average 
number of SDA labels (n) in the group (Table 3.2), calculated as follows: 
 
𝑛𝑛 =  
[(1)(number of peptides with 1 SDA)  + (2)(number of peptides with 2 SDA)
 + (3)(number of peptides with 3 SDA) +  (4)(number of peptides with 4 SDA)]
(Total number of labeled peptides (with 1 − 4 SDA) in the group)
 
 
A second bias may arise due to the number of tryptic peptides in each group. Groups with more 
peptides will generate larger crosslinking numbers, as the crosslinking number is a sum of the 
number of adducts obtained for all peptides within a group. For example, Group 1 has 1 tryptic 
peptide while Group 4 has 15 peptides (Table 3.2). Hence a larger crosslinking number for Group 
4 may not necessarily reflect more interactions, but may simply be a result of the number of 
peptides within the group. Crosslinking numbers were therefore normalized a second time by 
dividing by the number of tryptic peptides in each group (Table 3.2). 
 
3.4 RESULTS 
3.4.1 Intact Protein Labeling with SDA 
Following initial succinimidyl derivatization, Mb-SDA carrying up to five labels was detected by LC-
MS (Fig. 3.1). No significant secondary structural changes after SDA-labeling were detected using 
CD spectroscopy (Fig. 3.2A) and solid-state FTIR spectroscopy (Appendix, Fig. A4). However, this 
does not preclude any tertiary structure changes that may have occurred but were undetected by 
CD and FTIR. The relationship between the ratio (PX0/P0X) and SDA concentration (X) was 
consistent with second-order kinetics up to 0.51 mM SDA (Fig. 3.2B), further indication that minimal 
structural perturbation is induced by SDA labeling below this value. All further experiments were 
performed using a 10:1 ratio of SDA to protein with SDA concentrations below 0.51 mM to minimize 





Figure. 3.1. Deconvoluted mass spectrum of Mb labeled with 10x molar excess of SDA (0.39 mM 
SDA). Up to 5 labeled species were detected. Inset: Deconvoluted mass spectrum of Mb without 
SDA labeling. 
 
Figure 3.2. (A) Far-UV CD spectra of Mb without SDA labeling (dotted line) and Mb labeled with 




concentrations of SDA. [P], protein remaining unlabeled after quenching the labeling reaction; [P0], 
initial protein concentration; [X], SDA remaining unused after quenching the labeling reaction; [X0], 
initial SDA concentration. The plot shows linearity up to 0.51 mM SDA (no deviation of the second 
order rate constant) indicating minimal perturbation of tertiary structure.  
 
3.4.2 Peptide-Level Labeling with SDA 
LC/MS analysis with proteolytic digestion was conducted to identify the sites of attachment of the 
SDA to Mb via an NHS-linkage. Digestion of Mb-SDA yielded a total of 72 overlapping labeled 
tryptic fragments that provided complete sequence coverage (Fig. 3.3). LC-MS/MS analysis 
conclusively established that labeling occurred on the N-terminal Gly1, Lys42, Lys50, Lys56, Lys87 
and Lys147, consistent with the accepted reaction mechanism and with preferential labeling at 
primary amines by NHS esters at pH 7.4. In the peptides selected for MS/MS analysis, labeling 
was not detected on Lys16, Lys77, Lys78, Lys79, Lys96 and Lys118. For the other labeled peptides, the 
site of labeling could not be identified definitively at the amino-acid level due to low abundance and 
insufficient b- and y-ions. Interestingly, the peptide Asn140-Lys147 showed 4 SDA labels, although it 
contains only two Lys. Similarly, peptides Val17-Arg31 (containing no Lys), His119-Lys133 (one Lys) 
and Ala57-Lys63 (two Lys) each carried up to four SDA labels. This suggests that SDA does not 
label primary amines exclusively, but shows some reactivity towards other residues, as reported 






Figure 3.3. Amino acid sequence of Mb showing the domain organization with white cylinders 
representing the α-helices. Solid bars represent the tryptic peptides labeled with one SDA (white); 
two SDA (light grey); three SDA (dark grey) and four SDA (black). 
 
3.4.3 Crosslinking in the Solid State 
Mb-SDA irradiated in the solid state (with and without excipients) and digested with trypsin showed 
peptide-peptide, peptide-water and peptide-excipient adducts, as indicated by comparing the 
theoretical masses with the masses observed on LC-MS. The theoretically possible peptide-water 
and peptide-excipient adducts are listed in Table A4 (Appendix), allowing for a maximum of four 
SDA labels per tryptic peptide and up to four missed cleavages. A qualitative approach was used 
to describe the detectable interactions of the protein in lyophilized formulations. The criteria used 
for peptide selection and associated variability are described in Materials and Methods (refer 
section ‘Data Analysis For Qualitative Matrices’). Peptide-peptide adducts linked by up to 4 SDA 
for each formulation were mapped qualitatively as a symmetric matrix showing the interactions 
detected in three replicate LC-MS injections (Fig. 3.4). In the map, color intensity indicates the 




considered “detected” if one or more masses corresponding to the 2 peptides linked by 1 to 4 SDA 
was observed. The adducts detected in a single injection represent crosslinking between many 
pairs of protein molecules. 
 
Intermolecular peptide-peptide adducts were detected throughout the Mb sequence in all 
formulations (Fig. 3.4). The crosslinking reaction is not expected to favor a particular amino acid, 
since the photoactive diazirine generates a singlet alkyl carbene that reacts non-specifically with 
X-H groups (X = C, N, O, S) or C=C bonds on exposure to UV-A light 24. In the absence of excipient 
(‘control formulation’), adducts involving the CD, DE and EF loops and helix H were common, as 
shown in horizontal and vertical bands near the center and edge of the map (Fig. 3.4A). In 
formulations containing raffinose, adducts were more distributed than in the control formulation as 
shown by the spread of colored boxes in the matrix (Fig. 3.4B). In the Gdn HCl formulation, the 
map shows a number of interactions not detected in the control and raffinose formulations (Fig. 
3.4C), consistent with unfolding and increased molecular contacts. 
 
We infer that the peptide-peptide adducts for the control and raffinose formulations are 
intermolecular, since the calculated distance between the peptides in the crystal structure is greater 
than the length of the NHS spacer arm (3.9 Å) (PDB ID 1WLA; PyMOL Molecular Graphics System, 
Version 1.3, Schrödinger LLC). Although secondary structure changes in the control and raffinose 
formulations were not detected by CD and FTIR spectroscopy, it is possible that some 
intramolecular crosslinking may also have occurred as the result of tertiary structure perturbation. 
For the Gdn HCl formulation where the protein concentration (< 1% w/w) was low relative to the 
amount of Gdn HCl (~99% w/w) in the solid-state, the protein is considered to be fully denatured. 
At such a high excipient-to-protein ratio, it is likely that peptide-peptide adducts are the result of 
intramolecular interactions. However, intramolecular and intermolecular adducts cannot be 















Figure 3.4. Peptide-peptide adducts formed in (A) Mb-SDA alone (control), (B) Mb-SDA with 
raffinose and (C) Mb-SDA with Gdn HCl formulations. Peptide-peptide adducts detected in 
single (■), duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped 
irrespective of the number of SDA linkages (1-4 SDA). The -helices from N-terminus to C-
terminus in Mb are represented by cylinders labeled A to H respectively.  
*The molecular mass of tryptic fragments 63-77 and 64-78, 63-78 and 64-79 are identical and 




(32-47 x 43-45); (79-87 x 51-63) and (78-87 x 51-62); (63-78 x 57-63) and (63-79 x 57-62) are 
identical and cannot be differentiated. 
 
Peptide-water (and peptide-raffinose) adducts were mapped similarly for each formulation (both in 
solid- and solution state), by considering up to 4 water or raffinose molecules crosslinked with a 
peptide via up to 4 SDA (Fig. 3.5 and Fig. A6 in Appendix). 40 overlapping tryptic peptides labeled 
with 1 to 4 SDA molecules were found to interact with water and raffinose and were selected for 
the matrix. Peptide-water adducts were distributed across the entire molecule for all three 
formulations. Qualitative differences were observed, with several adducts detected only in the Gdn 
HCl formulation (Fig. 3.5, columns E and F). Peptide-water adducts across helices D and E were 
fewer in the raffinose formulation (both solid and solution-state) than in the control and Gdn HCl 
formulations (columns C and D). Fewer peptide-raffinose adducts were detected for the solid-state 
formulation than in solution (columns G and H). Only raffinose adducts, and not raffinose 
pentahydrate, were detected. Peptide-Gdn adducts, although detected, are not reported since their 
masses could not be distinguished from those of some unlabeled peptides and their abundance 
was not sufficient to provide definitive MS/MS fragmentation patterns. 
 
3.4.4 Total Number of Adducts 
The total numbers of chemically distinct peptide-peptide, peptide-water and peptide-excipient 
adducts detected in lyophilized and solution-state formulations were counted and averaged across 
triplicate LC-MS injections (Table 3.3). The solid-state formulations showed significantly more 
peptide-peptide adducts than in solution (p < 0.05), with the maximum number observed in the 
presence of Gdn HCl. The number of peptide-water adducts was significantly greater (p < 0.05) in 
the solid state than in solution for the control and Gdn HCl formulations, but was less than in solution 
for the lyophilized raffinose formulation. The number of peptide-raffinose adducts in the solid state 
was also significantly lower than in solution. Comparing the number of peptide-peptide adducts 




significantly different from one another, whereas the numbers of peptide-water adducts across the 
three lyophilized formulations were significantly different (p < 0.05).  
 
Within the control formulation, the number of peptide-peptide adducts was similar to the number of 
peptide-water adducts in both solution- and solid state. In the presence of raffinose, more peptide-
peptide interactions were formed than peptide-water and peptide-raffinose interactions in the solid 
state, whereas more peptide-raffinose adducts were formed in solution. In the presence of Gdn 
HCl, the number of peptide-water adducts was slightly greater than peptide-peptide adducts in 
solution, but decreased in the solid state. 
 
Table 3.3. Total number of peptide-peptide, peptide-water and peptide-excipient adducts detected 
by LC-MS in solid- and solution-state Mb-SDA formulations without excipients, with raffinose and 
with Gdn HCl. The numbers represent the average number of adducts (± SD) from three LC-MS 
injections. 
Type of Adducts 
Number of Adducts Detected 
Mb-SDA Mb-SDA + Raffinose Mb-SDA + Gdn HCl 
Solid Solution Solid Solution Solid Solution 
Peptide-Peptide 44.7 ± 3.5 30.3 ± 0.6 50.7 ± 3.2 31.3 ± 1.2 105.0 ± 12.3 28.3 ± 2.1 
Peptide-Water 42.7 ± 3.8 30.0 ± 1.7 11.3 ± 1.2 19.7 ± 1.2 74.3 ± 10.2 34.3 ± 1.5 
Peptide-Excipient  N/A N/A 11.3 ± 0.6 41.3 ± 0.6 N/A a N/A a 
 
a Peptide-excipient adducts for the Gdn HCl formulation could not be identified unambiguously by 





Figure 3.5. Tryptic peptides of Mb detected as peptide-water adducts in (A) lyophilized Mb-SDA, 
(B) Mb-SDA solution, (C) Mb-SDA lyophilized with raffinose, (D) Mb-SDA solution with raffinose, 




peptides of Mb detected as peptide-raffinose adducts in (G) Mb-SDA lyophilized with raffinose and 
(H) Mb-SDA solution with raffinose formulations. Peptide-water adducts detected in single (■), 
duplicate (■) and triplicate (■) sample injection(s) and peptide-raffinose adducts detected in single 
(■), duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped 
irrespective of the number of water or raffinose molecules linked. The α-helices from N-terminus to 
C-terminus in Mb are represented by cylinders labeled A to H respectively.  
* The molecular mass of tryptic fragments 63-77 and 64-78; 63-78 and 64-79 are identical and 
cannot be differentiated. 
 
3.4.5 Peptide Crosslinking Numbers (X1n) and Formulation Effects 
To summarize the data and allow meaningful inferences about formulation differences at the local 
level, crosslinked peptides were assigned to 8 groups according to the overlapping tryptic 
fragments obtained (Table 3.2). Peptide crosslinking numbers (X1n) were calculated as described 
in Materials and Methods. Normalized X1n values (denoted X1n*) for each group were averaged 
across triplicate LC-MS measurements and expressed as mean ± standard deviation. The X1n* 
were compared: (1) across groups within a formulation and (2) within a group across formulations. 
One-way ANOVA demonstrated that the number of peptide-peptide adducts (X11*), peptide-water 
adducts (X12*) and peptide-excipient adducts (X13*) are significantly different across groups within 
a given formulation (p < 0.05). Comparing X1n* values for a group across formulations (p < 0.05) 
also showed significantly different means for all groups except Group (2) for X11*, based on Tukey’s 
post-hoc analysis.  
 
The crosslinking numbers can be used to compare interactions within and between formulations. 
For the lyophilized formulation without excipients (control formulation), the sum of group X11* values 
(denoted as ΣX11*) for Mb-SDA was 6.8 (± 1.7) (Table 3.4), a weighted measure of the total number 
of distinct peptide-peptide adducts formed. Similarly, ΣX12*, the sum of X12* values for this 




formed.  In this formulation, the greatest X11* values were observed for Groups (4), (6) and (8), 
consistent with greater involvement in protein-protein interactions in these regions (Fig. 3.6A, white 
bars).  X11* values for these groups were significantly greater than values for the other groups. 
Group (5) showed the greatest number of peptide-water adducts (X12*), while the remaining groups 
did not show significantly different X12* values (Fig. 3.6B, white bars). 
 
Table 3.4. Crosslinking numbers for peptide-peptide adducts (X11*) values (± SD, n=3) for each 
lyophilized formulation. 
Group 
X11* (± SD) 
Control Raffinose Gdn HCl 
1 0.7 ± 0.6 1.7 ± 0.6 4.7 ± 0.6 
2 0.4 ± 0.4 1.2 ± 0.4 1.6 ± 0.7 
3 0.4 ± 0.2 0.9 ± 0.0 1.9 ± 0.3 
4 1.0 ± 0.1 0.9 ± 0.1 2.6 ± 0.4 
5 0.3 ± 0.6 0.8 ± 0.1 1.4 ± 0.1 
6 1.8 ± 0.3 2.1 ± 0.3 3.4 ± 0.2 
7 0.9 ± 0.2 0.4 ± 0.2 2.2 ± 0.3 
8 1.2 ± 0.1 1.6 ± 0.2 2.6 ± 0.3 











X12* (± SD) 
Control Raffinose Gdn HCl 
1 0.3  ± 0.6 1.0  ± 0.0 2.0  ± 0.0 
2 0.9  ± 0.2 0.4  ± 0.0 1.5  ± 0.2 
3 0.4  ± 0.0 0.3  ± 0.1 1.4  ± 0.3 
4 0.3  ± 0.1 0.0  ± 0.0 0.4  ± 0.1 
5 3.3  ± 0.1 2.2  ± 0.5 2.9  ± 0.4 
6 0.9  ± 0.1 0.4  ± 0.0 1.0  ± 0.4 
7 0.3  ± 0.1 1.0  ± 0.0 1.1  ± 0.0 
8 0.3  ± 0.3 0.2 ± 0.1 0.7  ± 0.1 
Total (ΣX12*) 6.8  ± 0.9 5.6  ± 0.5 11.0  ± 1.0 
Note: The moisture contents of the control, raffinose and Gdn HCl formulations were 1.03 %, 














Table 3.6. Crosslinking numbers for peptide-raffinose adducts (X13*) values (± SD, n=3) for Mb-
SDA lyophilized and crosslinked in the presence of raffinose. 
Group X13* (± SD) 
1 0.0 ± 0.0 
2 0.0 ± 0.0 
3 0.1 ± 0.1 
4 0.2 ± 0.0 
5 0.1 ± 0.1 
6 a 0.2 ± 0.1 
7 0.2 ± 0.0 
8 0.2 ± 0.0 
Total (ΣX13*) 1.9 ± 0.2 
a Note that Group (6) (spanning Lys78-Lys98) was expanded slightly to Lys79-Lys102 to accommodate 
peptide Lys79-Lys102 that was found to form a raffinose adduct. 
 
 
Figure 3.6. (A) Peptide-peptide adducts, (B) Peptide-water adducts and (C) Peptide-raffinose 
adducts detected by LC-MS. White bars represent Mb-SDA lyophilized in the absence of excipients 
(blank), grey bars represent Mb-SDA lyophilized with raffinose and black bars represent Mb-SDA 
lyophilized with Gdn HCl. X1n values were counted for peptides assigned to 8 groups. Bars 




Group (6) spanning residues Lys78-Lys98 was expanded to Lys78-Lys102 to accommodate peptide 
Lys79-Lys102 which was found to form raffinose adducts. 
 
In the lyophilized raffinose formulation, ΣX11* was 43 % greater than the excipient-free control (Table 
3.4, Fig. 3.7A, grey bars), consistent with an increase in the number of distinct peptide-peptide 
adducts, although this was not a significant increase.  ΣX12* for this formulation was 31% less than 
control, consistent with fewer distinct peptide-water adducts (Table 3.5, Fig. 3.7B, grey bars). The 
X12* values differed among the peptide fragment groups in the raffinose formulation (Table 3.5, Fig. 
3.6B, grey bars). Group (5) again showed the greatest X12* value, while Groups (2), (3), (4), (6) and 
(8) showed X12* values < 1.0. Various peptide-raffinose adducts were also detected in the solid-
state, with the maximum X13* for Group (6) (Table 3.6, Fig. 3.6C). 
 
 
Figure 3.7. Total number of peptide-peptide (A), peptide-water (B) and peptide-raffinose (C) 
adducts observed for the protein in solution and solid-state (Mean ± SD (n=3)). White bars 
represent solution-state adducts and black bars represent adducts observed in the lyophilized 
formulation. 
 
In the lyophilized Gdn HCl formulation, the ΣX11* value was 3 times greater than the control, 
indicating more distinct peptide-peptide adducts (Table 3.3, Fig. 3.7A, black bars). ΣX12* for this 
formulation was 1.6 times greater than the control, indicating more distinct peptide-water adducts 




(2). Within the formulation, the maximum X11* values were observed for Groups (1) and (6), followed 
by Groups (4) and (8) (Fig. 3.6A, black bars). X12* values were significantly greater than in the 
control formulation for all groups except Groups (4), (5) and (6) (Fig. 3.6B, black bars). The overall 
increase in X1n* values is consistent with protein unfolding (as confirmed by CD and FTIR 
spectroscopy) and increased interactions with the matrix. 
 
Comparing ΣX11* and ΣX12* values across lyophilized formulations, the numbers of peptide-peptide 
and peptide-water interactions were significantly greater in the Gdn HCl formulation (Fig. 3.7A, B). 
Comparing ΣX11* values across solution state formulations, peptide-peptide interactions were 
significantly greater in the Gdn HCl formulation, while ΣX12* values were similar across all three 
solution formulations (Fig. 3.7A, B). Comparing solution- and solid-state formulations, ΣX11* values 
were greater in the lyophilized raffinose and Gdn HCl formulations than in the corresponding 
solution formulations, while ΣX12* for lyophilized Gdn HCl formulation was significantly greater than 
in the solution state. Peptide-raffinose adducts (ΣX13*) for the solution-state raffinose formulation 
were significantly greater than in the solid state (Fig. 3.7C).  
 
To determine the physical form of the excipient in the solid state, the lyophilized formulations were 
examined using X-ray diffraction. The control and raffinose formulations remained amorphous while 
the Gdn HCl formulation showed crystalline features, suggesting that the excipient had crystallized 
(data not shown). To relate the formation of peptide-water adducts to overall moisture content, the 
moisture content was determined using gravimetric analysis. The moisture contents of the control, 
raffinose and Gdn HCl formulations were 1.03%, 1.92% and 0.04% (w/w), respectively (Appendix, 
Fig. A8). The raffinose formulation showed the fewest peptide-water adducts (Table 3.4, Fig. 3.7B), 
although it had the highest gravimetric water content. Conversely, the Gdn HCl formulation had the 






The results presented here demonstrate that ssPC-MS can be used to map the protein 
microenvironment in lyophilized formulations with peptide-level resolution, providing information on 
the interactions of protein side chains with water, excipients and other protein molecules. Methods 
such as FTIR and DSC are routinely used to characterize lyophilized proteins, but provide only bulk 
information for the protein or matrix as a whole.  ssPC-MS probes the protein side-chain 
environment with high resolution at the local level, based on qualitative determination of the types 
of adducts formed and quantitative crosslinking numbers (X1n). To our knowledge, this is the first 
time that protein-protein and protein-matrix interactions have been mapped directly in the solid 
state. 
 
The interaction maps show specific protein-matrix interactions at the peptide level and reflect the 
heterogeneous nature of the lyophilized matrix (Fig. 3.4 and 3.5, Appendix Fig. A5 and A6). Not all 
theoretically possible adducts were observed, as shown by the white boxes in the interaction maps 
(Fig. 3.4 and 3.5, Appendix Fig. A5 and A6). The distribution of the peptide-peptide adducts 
(colored or shaded boxes) across the maps suggests that Mb molecules are oriented in the solid 
matrix in several different ways, allowing different adducts to be formed with the same peptide. 
Despite the lack of long-range order, there appear to be constraints in the control and raffinose 
formulations that prevent the formation of many of the theoretically possible adducts (white boxes). 
That these constraints are related to protein structure is supported by the presence of a greater 
number of unique adducts in the Gdn HCl formulation. 
 
The interactions detected by ssPC-MS provide additional information about protein structure and 
environment in the solid matrix. For example, several peptide-peptide adducts were observed in 
the control and raffinose formulations for peptides spanning the CD, DE and EF loop regions (Fig. 
3.4A, B). Motions of loop regions are linked to conformational transitions involving the helices of 




are especially flexible, allowing for efficient ligand binding26-28. This loop flexibility may result in 
better protein-protein contacts in the solid state. Any disruption of the salt bridge between residues 
Lys45 and Asp60 that normally stabilizes the DE link with the CD loop 29, 30 could also contribute to 
increased loop mobility in lyophilized solids and make the loop regions more prone to interactions.  
 
In contrast to the loop interactions, peptide-peptide adducts were rarely observed for helices A and 
G in the control and raffinose lyophilized formulations. In the folding pathway of holoMb, helices A, 
G and H fold first and form a stable molten globule core31, 32. This is followed by folding of helices 
B, C, D, E and F and heme coordination in a hydrophobic pocket between helices E and F. The 
structure of holoMb is further stabilized by interhelix contacts between helices B-G, B-E, G-H, F-H, 
A-E and A-H25, 33. Here, limited crosslinking for helices A and G may be explained by persistence 
of the molten globule in the solid state. However, helix H formed several peptide-peptide adducts 
despite being part of the molten globule. Previous ssHDX-MS have shown loss of backbone 
protection in helix H upon lyophilization15, which may result in increased crosslinking for helix H. 
No peptide-peptide crosslinking was observed between helices B-G, B-E, G-H and A-E in the 
control and raffinose lyophilized formulations (Fig. 3.4A, B), perhaps as a result of interhelix 
interactions preserved in the solid state and the inability of the side-chains to participate in 
crosslinking. 
 
The results show that crosslinking provides high-resolution information about protein-matrix 
interactions in both solution and solid state.  While data matrices (Fig. 3.4 and 3.5) can be used to 
qualitatively describe the type of adducts formed, the number of adducts (Table 3.3) can be used 
as a simple metric to quantify the fraction of interactions with each matrix component. The number 
of peptide-matrix adducts can be affected by events such as unfolding, phase separation and 
aggregation. Similar numbers of peptide-peptide and peptide-water adducts in the control 
formulation (Table 3.3) suggest that there is equal likelihood of protein-protein and protein-water 




The presence of interacting excipients and the nature of the interaction is expected to alter the 
number of adducts, as observed with raffinose and Gdn HCl (Table 3.3). 
 
Low X11* and high X12* values for E helix in all the three formulations suggest that the side-chains in 
this region interact primarily with water. HoloMb contains a distal His64 residue (helix E) in the heme-
binding pocket; this residue is involved in modulating heme-ligand affinity by binding to water 34, 35. 
This suggests that there is a hydration layer around helix E, in which may be responsible for the 
high frequency of water adducts with helix E peptides. Interestingly, the sites (peptides) of raffinose 
crosslinking were not coincident with the sites for water crosslinking, even in solution (Fig. 3.5; only 
2 peptides Lys46-Lys56 and Lys63-Lys77/Lys64-Lys78 out of 22 showed crosslinking with both water 
and raffinose). Such observations have implications regarding the water replacement hypothesis, 
as discussed below. The effects of Gdn HCl on local protein structure could be established, as 
observed by the increased peptide-peptide crosslinking in the solid state (Fig. 3.4C). That X11* and 
X12* values for most groups were greater in the Gdn HCl formulation than in the other two is also 
consistent with greater matrix exposure. 
 
The water replacement hypothesis states that lyophilized proteins are stabilized by hydrogen bonds 
to sugars and other excipients in the dried state, which replace the hydrogen bonds to water that 
stabilize the structure in solution 36. Previous studies have tested this hypothesis by measuring the 
extent of hydrogen bonding using the FTIR band area at 1583 cm-1, which corresponds to 
carboxylate- hydrogen bonding8, 37. The band area was found to be smaller in proteins lyophilized 
in the absence of carbohydrate excipients, but increased with increasing carbohydrate 
concentration 8. Though FTIR results provide some support for the water replacement hypothesis, 
ssPC-MS allows these interactions to be interrogated directly. The presence of peptide-water 
adducts in all three formulations studied here confirms that residual water is present at the protein 
surface after lyophilization (Fig. 3.5A-F). Overall peptide-peptide interactions increased in the solid 




is expected as a result of freeze-concentration and increased protein-protein contacts. The 
magnitude of this increase in protein-protein contacts is greatest in the lyophilized Gdn HCl 
formulation (Fig. 3.7A). This is in part due to protein unfolding and also a possible result of Gdn 
HCl crystallization. In solution, Gdn HCl binds to proteins and promotes unfolding. This binding may 
explain the absence of more peptide-water adducts in the solution Gdn HCl formulation (Table 3.3, 
Fig. 3.7B), even though the protein is partially unfolded at 1.5 M Gdn HCl 38. We hypothesize that 
when Gdn HCl crystallizes, the SDA-labeled residues are free to crosslink with water molecules, 
resulting in increased ΣX11* and ΣX12* in the solid state compared to solution. 
 
Preferential exclusion of carbohydrates is known to occur in solution at concentrations ≥ 0.2 M 39, 
40. In this study, raffinose was present at a concentration of ~ 2 mM; in such a dilute solution, it is 
unlikely that there is appreciable raffinose exclusion. Hence, increased molecular mobility and 
diffusion in solution are more likely to contribute to the observed protein-raffinose crosslinking. 
While peptide-peptide crosslinking was greater in the lyophilized raffinose formulation than in 
solution (Table 3.3, Fig. 3.7B), peptide-raffinose adducts were fewer in the solid state than in 
solution (Table 3.3, Fig. 3.7C). Although the reduced mobility in the solid state is expected to 
produce a greater number of intermolecular contacts and crosslinked adducts, the observed results 
may be due to raffinose micro-phase separation in the solid state or water replacement by raffinose 
in the solid state. If hydrogen bonds between Mb and raffinose in the solid state indeed replaced 
hydrogen bonds to water in solution, one would expect to observe new peptide-raffinose adducts 
in the solid state that were not observed in solution. In addition, these new raffinose adducts should 
be detected in peptides for which peptide-water adducts were observed in solution. Neither of these 
was observed with SDA crosslinking in solution- and solid-state raffinose formulations. A 3:1 w/w 
ratio of raffinose to protein translates to about 100 molecules of raffinose per protein molecule, so 
that it is unlikely that the solid is too dilute in raffinose, at the bulk level, for reaction with SDA to 
occur. Thus, water replacement is the less likely explanation for the peptide-water and peptide 




crystallization and phase separation of raffinose during annealing, although the final lyophilized 
product was amorphous 41. In this work, the lyophilized raffinose formulation was amorphous as 
observed by X-ray diffraction (data not shown), but raffinose crystallization during freezing or micro- 
phase separation in the lyophilized product may have occurred and would not be detected. The 
extent to which the hygroscopic nature of raffinose and raffinose-water hydrogen bonding 
contributes to decreased peptide-water interactions in the lyophilized raffinose formulation is also 
unknown. Moreover, the relative reactivity of the carbene in the solid and solution states and as 
well as its rates of reaction with raffinose and water may also contribute, and to date have not been 
explored.  
 
While ssPC-MS offers higher resolution structural information than conventional methods such as 
FTIR, experimental and computational limitations remain and should be noted. A current 
experimental limitation is the inability to resolve the sites of crosslinking at the amino-acid level with 
ESI-CID-MS/MS. Higher resolution mass spectrometry instruments (e.g., FTICR-MS) may be 
useful for this purpose. Analysis could be simplified by better control of the sites and extent of 
protein derivatization. This could be accomplished through optimizing pH, SDA concentration and 
reaction time to limit labeling at side-chains that do not contain a primary amine, or by the use of 
site-specific derivatization chemistries (e.g., click chemistry). Computationally, though theoretical 
mass lists for derivatized and crosslinked peptides can be prepared using software such as 
GPMAW, the complete list can be quite long, particularly for larger proteins such as antibodies. In 
addition, matching the theoretical list with observed masses using software such as MassHunter 
can be time-consuming due to potential false positives that need to be verified manually. Recent 
improvements in bioinformatics such as xProphet could allow improved identification of crosslinked 
peptides with low false positive rates42. However this technique requires MS/MS information, 
preferably from high-resolution LTQ-Orbitrap instruments. More broadly, the effects of water activity 
(RH) and excipient type on protein-protein and protein-matrix interactions require further 




Nevertheless, the results presented here demonstrate the potential of ssPC-MS for probing protein-
protein and protein-matrix interactions in lyophilized solids with high resolution. 
 
3.6 CONCLUSIONS 
ssPC-MS provided qualitative and quantitative measures of protein side-chain interactions in 
lyophilized formulations. The environment of lyophilized Mb could be visualized with high resolution 
at the peptide-level and excipient differences quantified using X1n* values.  
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CHAPTER 4. STUDYING PROCESS AND FORMULATION EFFECTS ON PROTEIN 
STRUCTURE IN LYOPHILIZED SOLIDS USING MASS SPECTROMETRIC METHODS 
4.1 ABSTRACT 
Myoglobin (Mb) was lyophilized in the absence (Mb-A) and presence (Mb-B) of sucrose in a pilot-
scale lyophilizer with or without controlled ice nucleation. Cake morphology was characterized 
using scanning electron microscopy (SEM) and changes in protein structure were monitored using 
solid-state Fourier-transform infrared spectroscopy (ssFTIR), solid-state hydrogen-deuterium 
exchange-mass spectrometry (ssHDX-MS) and solid-state photolytic labeling-mass spectrometry 
(ssPL-MS). The results showed greater variability in nucleation temperature and irregular cake 
structure for formulations lyophilized without controlled nucleation. Controlled nucleation resulted 
in nucleation at ~ -5 °C and uniform cake structure. Formulations containing sucrose showed better 
retention of protein structure by all measures than formulations without sucrose. Samples 
lyophilized with and without controlled nucleation were similar by most measures of protein 
structure. However, ssPL-MS showed the greatest pLeu incorporation and more labeled regions 
for Mb-B lyophilized with controlled nucleation. The data support the use of ssHDX-MS and ssPL-
MS to study formulation and process-induced conformational changes in lyophilized proteins. 
 
4.2 INTRODUCTION 
Proteins are often marketed in lyophilized form or stored as lyophilized powders after purification 
and prior to formulation. Lyophilization begins with freezing, followed by primary drying to remove 
bulk ice by sublimation and secondary drying to desorb unfrozen water. Proteins are subjected to 
various stresses during lyophilization, including freeze-concentration and denaturation at the ice-
surface, pH shifts and dehydration-induced aggregation 1-4. Proteins can be protected from some 




process itself can play a role in determining critical quality attributes (CQAs) of the product. For 
example, the cooling rate and type of thermal treatment used may result in entrapment of 
metastable intermediates that can crystallize at higher temperatures during manufacturing or 
storage 9-11. Inadequate drying temperature or time can also result in product failure due to 
increased moisture content, and processing or storage above the glass transition temperature (Tg) 
can result in degradation 12, 13. Cake elegance can be adversely affected by aggressive processing 
above the collapse temperature, producing various degrees of macro- and micro-collapse 14, 15. 
Higher temperatures during lyophilization can degrade reducing carbohydrate excipients via the 
Maillard reaction 16, which may reduce their stabilizing effects. 
 
The freezing step is critical, since parameters such as the degree of supercooling and rate of 
freezing can affect the morphology of ice crystals, which in turn affects the rate of primary drying 17, 
18. When a solution is supercooled to a large degree, ice nucleation occurs at lower temperatures 
with little time for ice crystal growth, resulting in smaller pores in the dried solid. These small ice 
crystals result in small pores and offer greater resistance to flow of water vapor through the porous 
bed of partially dried solids. This necessitates the use of a longer primary drying step to remove 
crystalline water.  In contrast, a lower degree of supercooling is associated with a slower rate of 
freezing from a relatively small number of large ice crystals. Since ice nucleation is stochastic, 
cycles without controlled freezing are expected to nucleate over a range of temperatures, resulting 
in longer freezing times and heterogeneous ice crystal morphology. Variability is also introduced 
by vial position within the lyophilizer chamber 19, since vials near the door and walls of the lyophilizer 
chamber receive more heat via radiation than those near the center of the chamber. Together, 
these factors result in inter-vial- and inter-batch heterogeneity. If left uncontrolled, this variability 
may be magnified when a process is scaled from a laboratory bench-top lyophilizer to a production 
freeze-dryer. Heat- and mass-transfer differences between pilot and production freeze-dryers may 
also play a role, so that the same lyophilization cycle may produce variable product CQAs at 




resulting in less variability between samples and faster drying. The freezing rate can also affect 
product stability, since smaller ice crystals formed by fast freezing present a greater surface area 
for potential protein adsorption and unfolding. Aggregation at the protein solution-ice interface was 
implicated in the lyophilization-induced instability of human growth hormone 20, recombinant human 
factor XIII 21, lactate dehydrogenase and immunoglobulin G 3.  
 
Strategies to control nucleation include the use of an ice fog as a seeding technique and rapid 
depressurization to induce spontaneous nucleation. While the effect of controlled ice nucleation on 
primary drying time has been well documented 22-25, its effect on protein structure is not well 
understood. Controlled nucleation at a lower degree of supercooling results in larger ice crystals 
with lower surface area for protein adsorption. In addition, since all vials nucleate at the same time 
and primary drying time is decreased, the residence time of proteins at the ice surface is reduced. 
These two factors are expected to produce a product that is more stable than one lyophilized 
without controlled nucleation. The effect of depressurization-induced controlled nucleation on 
product characteristics was reported for a monoclonal antibody 26. Although the drying time was 
reduced by ~ 10 h and cake appearance improved to some extent with controlled nucleation, there 
was no significant impact on aggregation as detected by UV spectroscopy and size exclusion 
chromatography (SEC). Secondary structure was not altered significantly, as quantified by circular 
dichroism (CD) spectroscopy. The process did not affect binding to protein-A, suggesting that the 
tertiary structure was also intact, at least at the binding site. Other studies investigated the effect of 
different lyophilization cycles on protein conformation and cake structure 27, 28. While cycle 
variations typically led to altered cake morphology as detected using scanning electron microscopy 
(SEM), conformational changes could not be detected using conventional ssFTIR and solution-
state CD and fluorescence spectroscopy. 
 
In this work, the effects of controlled nucleation and lyophilizer scale on protein structure were 




Myoglobin (Mb) lyophilized in a LyoStar freeze-dryer with or without controlled nucleation showed 
no significant changes in structure at the backbone and side-chain levels, as determined by ssFTIR, 
solid-state hydrogen-deuterium exchange (ssHDX-MS) and solid-state photolytic labeling (ssPL-
MS), respectively. However, formulation effects were dominant and protein structure was better 
protected at the backbone in the presence of sucrose. The results indicate that local structure 
remains unaltered by controlled nucleation and that ssHDX-MS and ssPL-MS can be used to detect 
process- and formulation-induced changes in protein structure. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Materials 
Equine skeletal muscle holomyoglobin (Mb), sucrose, potassium phosphate dibasic and 
ammonium bicarbonate were purchased from Sigma Aldrich (St. Louis, MO). Potassium phosphate 
monobasic (anhydrous) was purchased from Amresco (Solon, OH). D2O was obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, MA) and photo-leucine (L-2-amino-4, 4′-
azipentanoic acid) from Thermo Scientific (Rockford, IL). Mass spectrometry-grade water, 
acetonitrile and formic acid were purchased from Fisher Scientific (Fair Lawn, NJ). Spectra/Por 
dialysis tubing (MWCO 8000-10000 Da) was used to dialyze the protein prior to formulation 
(Spectrum Laboratories, Inc., Rancho Dominguez, CA). Syringes (Beckton, Dickinson and 
Company, Franklin Lakes, NJ) and 0.2 µm Acrodisc® syringe filters (Pall Corporation, Ann Arbor, 
MI) were used to filter the dialysate. 
 
4.3.2 Sample Preparation 
Mb was dissolved in potassium phosphate buffer (2.5 mM, pH 7.4) and dialyzed overnight against 
the same buffer using dialysis tubing. The dialyzed protein was filtered using a syringe filter and its 
concentration measured using UV spectroscopy (8453 UV-Vis, Agilent Technologies, Santa Clara, 
CA) and the molar extinction coefficient ε555 nm = 12.92 mM-1cm-1 (obtained from Sigma Aldrich 




solution (345 µM) was used for all formulations. A 20 mg/mL stock solution of sucrose was prepared 
by dissolving sucrose in potassium phosphate buffer (2.5 mM, pH 7.4) and stored at 4 °C until use. 
Similarly, a 30.9 mM stock solution of photo-leucine (pLeu) was prepared using the same buffer 
and stored at 4 °C until use. 
 
Two formulations were prepared for lyophilization: a control formulation containing Mb and buffer 
(‘Mb-A’) and a formulation containing Mb, sucrose and buffer (‘Mb-B’). Stock solutions of Mb, 
sucrose and buffer were mixed such that the final Mb concentration was 70 µM and the ratio of Mb 
to sucrose was 1:1 w/w. For photolytic labeling studies, pLeu was added to Mb-A and Mb-B such 
that the molar ratio of pLeu to Mb was 100:1. The weight fractions of each component are listed in 
Table 1. The formulations were filled in glass tubing vials (USP Type I glass; 2 ml capacity) with 13 
mm necks. The fill volume was 500 µL for ssHDX-MS, ssPL-MS, thermogravimetric analysis, X-ray 
diffraction and solid-state Fourier-transform infrared spectroscopy samples. A 3 mL fill in 10 mL-
capacity glass beakers was used for scanning electron microscopy. 
 
Table 4.1. Weight fractions of components of lyophilized formulations 
Lyophilized Formulation 
% w/w 
Mb a Sucrose a Buffer pLeu a 
Mb-A  91.7 N/A 8.3 N/A 
Mb-B  42.9 42.9 14.1 N/A 
Mb-A + pLeu 46.0 N/A 15.1 38.8 
Mb-B + pLeu 31.5 31.5 10.4 26.6 
a Mb, myoglobin; pLeu, photo-leucine (L-2-amino-4,4′-azipentanoic acid) 
 
4.3.3 Lyophilization 
Both Mb-A and Mb-B formulations were lyophilized with and without controlled nucleation during 




Inc., Gardiner, NY), the vials were equilibrated at 5 °C for 30 min, followed by pressurization with 
argon gas to 28 psig and a decrease in temperature to -5 °C. A ramp rate of 1 °C/min was used 
and the vials were equilibrated at -5 °C for 60 min. At the end of this step, the chamber was rapidly 
depressurized to 1 psig to induce controlled nucleation and the temperature was further reduced 
to -45 °C at a ramp rate of 1 °C/min and held overnight to complete the freezing step. For freezing 
without controlled nucleation (LyoStar II, SP Industries), the vials were equilibrated at 5 °C for 60 
min (ramp rate 1 °C/min) and then frozen at -45 °C overnight. 
 
To minimize process variability, vials frozen with and without controlled nucleation were dried 
simultaneously in the LyoStar 3 lyophilizer. Vials frozen without controlled nucleation in LyoStar II 
were quickly transferred to LyoStar 3 and held at -45 °C for an additional 30 min. A vacuum of 70 
mTorr was used and the shelf temperature was increased stepwise with a ramp rate of 1 °C/min (-
35 °C for 600 min, -20 °C for 600 min, -5 °C for 360 min, 10 °C for 360 min). Product temperature 
was monitored during freezing and drying using 30 gauge Type T thermocouple sensors. 
Thermocouples were placed either inside the solution or taped to the outside of the vial. Chamber 
pressure was monitored using a capacitance manometer (CM) and Pirani gauge. The end point of 
each drying step was determined using a pre-set CM/Pirani gauge differential, wherein the cycle 
advanced to the next step if the differential was reached at the end of the previous step. Since the 
presence of thermocouples inside the solution may affect sample integrity, thermocouple-
containing vials were not used for characterization studies. 
 
4.3.4 X-ray Powder Diffraction 
Samples were analyzed by X-ray powder diffraction to detect any crystallinity after lyophilization. 
Diffractograms were collected on a 2θ θ scan from 7-35° 2θ with 0.02° increments using a 





4.3.5 Scanning Electron Microscopy (SEM) 
Intact lyophilized cakes were removed from beakers and mounted on a sample holder with double-
sided tape. The cakes were carefully sliced using a blade and sputter-coated with carbon graphite. 
Images were obtained using a JCM-6000 NeoScope benchtop instrument (JEOL USA, Peabody, 
MA) in the high vacuum, 15 kV mode. 
 
4.3.6 Solid-State Fourier Transform Infrared (ssFTIR) Spectroscopy 
FTIR spectra were acquired for all lyophilized samples using a Tensor 37 spectrometer (Bruker 
Optics, Billerica, MA), as described previously 29. 128 scans were obtained at 4 cm-1 resolution and 
spectra were processed using OPUS software (v. 6.5, Bruker Optics), by cutting around 1600-1700 
cm-1, smoothing and baseline correcting before obtaining second derivative spectra. 
 
4.3.7 Thermogravimetric Analysis (TGA) 
Moisture sorption kinetics was measured using TGA (QA5000SA, TA Instruments, New Castle, DE) 
to study its effect on hydrogen-deuterium exchange kinetics. ~ 1 mg of lyophilized protein (with or 
without sucrose) was loaded onto a metallized quartz sample pan. The loosely bound water was 
removed by heating the sample to 40 °C, 0 % RH inside the sample chamber until the weight 
change was < 0.01 % and equilibrated for 1 h. The sample was then equilibrated at 5 °C, 0 % RH 
for 1 h, followed by moisture sorption at 5 °C, 43 % RH for 3 h inside the sample chamber. Initial 
moisture content was calculated from the weight change before and after equilibration at 40 °C, 0 % 
RH for 1 h. 
 
4.3.8 Solid-state Hydrogen Deuterium Exchange- Mass Spectrometry (ssHDX-MS) 
Lyophilized vials were uncapped and placed in a sealed desiccator equilibrated at 43 % RH over 
D2O (obtained with a saturated solution of potassium carbonate in D2O). HDX was allowed to 




stoppered and flash-frozen in liquid N2 to quench the exchange reaction. The samples were stored 
at -80 °C until analysis. 
 
HPLC-MS (1200 series HPLC, ESI-qTOF 6520, Agilent Technologies, Santa Clara, CA) was used 
to measure deuterium uptake at the intact level, as described previously 29, 30. Deuterated samples 
were reconstituted with 2 mL of ice-cold quench buffer (5 % methanol, 0.2 % formic acid in LC-MS-
grade water, pH 2.5) and injected into a refrigerated box housing the HPLC valves, tubing and 
protein microtrap at ~ 0 °C to reduce back-exchange. The protein was eluted with a gradient mobile 
phase that increased from 30 % to 80 % acetonitrile over 3 min. Mass spectra for deuterated 
samples were deconvoluted using MassHunter software (Agilent Technologies), and the number 
of deuterons incorporated was calculated by subtracting the mass of the undeuterated protein from 
the mass of the deuterated protein. Peak widths of the deconvoluted intact protein spectra were 
measured at 20 % peak height. 
 
4.3.9 Solid-state Photolytic Labeling- Mass Spectrometry (ssPL-MS) 
Lyophilized Mb-A and Mb-B vials containing pLeu were uncapped and irradiated at 365 nm for 40 
min using Stratalinker 2400 (Stratagene Corp., La Jolla, CA) as described previously 31. The cakes 
were then reconstituted with 500 µL ammonium bicarbonate (100 mM, pH 8.0), diluted to 20 pmol 
and analyzed at the intact protein level by LC-MS. The same elution parameters were used as 
described above for ssHDX-MS, but with analysis performed at room temperature since the pLeu 
label does not undergo back-exchange. The fractions of protein populations with 0-2 labels (F L=0, 











To identify the sites of labeling at the peptide level, the labeled Mb formulations were digested with 
trypsin (1:10 ratio of trypsin to protein) at 60 °C for 16 h. Labeled peptides were analyzed by LC-
MS using the method described previously 31 and identified with MassHunter, using a theoretical 
mass list of tryptic peptides with up to 2 labels. 
 
4.3.10 Statistical Analysis 
Process- and excipient effects on protein structure were compared statistically using GraphPad 
Prism software (GraphPad software, version 6; La Jolla, CA). One-way ANOVA followed by Tukey’s 
test was used for multiple comparisons (p = 0.05). 
 
4.4 RESULTS 
In the absence of solution and vial impurities, a solution can remain in a supercooled liquid state 
without undergoing phase transition into a solid as the temperature is lowered below its freezing 
point. When water crystallizes into ice, an increase in product temperature is detected associated 
with the latent heat of fusion. Product temperature bias due to the presence of the thermocouple in 
solution must be considered, since it can increase the nucleation temperature 32. To avoid 
thermocouple-related artifacts in temperature, some thermocouples were taped to the outside of 
the vial. Vials with thermocouples also tend to dry faster, since ice nucleation at higher 
temperatures produces larger ice crystals with lower resistance during drying 33. Although vials with 
thermocouples may not measure true product temperature, a comparison of product temperatures 
between processes can still be made using thermocouple-containing vials. 
 
4.4.1 Effect of Freezing Step on Nucleation Temperature 
Product temperatures for Mb-A (excipient-free formulation) and Mb-B (sucrose-containing 
formulation) frozen with and without controlled nucleation were recorded (Fig. 4.1 A, B). In the 
absence of controlled nucleation, variable nucleation temperatures were recorded ranging from -




10 min. With controlled nucleation, all the vials containing thermocouples inside the solution 
nucleated simultaneously at -5.3 ± 0.2 °C (Fig. 4.1B), irrespective of formulation. Vials with 
thermocouples taped to the outside reported nucleation temperatures of -4.0 °C (Mb-A) and -4.4 °C 
(Mb-B) with controlled nucleation. 
 
 
Figure 4.1. Product temperature profiles for excipient-free (Mb-A) and sucrose-containing (Mb-B) 
myoglobin lyophilized without controlled nucleation (panel A) and with controlled nucleation (panel 
B). Thermocouple probes (TC) were placed inside the vial (labeled Mb-A in, Mb-B in) or taped to 
the outside of the vial (labeled Mb-A out, Mb-B out). The shelf set point (shelf SP) temperature is 
represented by the black line in panels A and B. 
 
4.4.2 Measurement of Supercooling during the Freezing Step 
To estimate the extent of supercooling in freezing with uncontrolled nucleation, thermocouples were 
taped to the outside of the vial to avoid thermocouple-related bias. However, this may introduce 
uncertainty as a thermal lag is expected for thermocouples placed on the outside of the vial. Hence 
thermocouples were placed both outside and inside the vial for 2 vials each for Mb-A and Mb-B. 
These thermocouples reported similar temperatures, suggesting that thermal lag was minimum and 
the nucleation temperature recorded was reproducible (Fig. 4.2 A, B). Mb-A showed supercooling 
to ~ -7.5 ± 0.4 °C and Mb-B showed supercooling to ~ -9.1 ± 0.4 °C, as measured by thermocouples 
placed both inside and outside the vial. Moreover, vials with thermocouples only in contact with the 




The reason for this is unclear and the data are contrary to the expected result of increased 
nucleation temperature due to the presence of the thermocouple. 
 
 
Figure 4.2. Extent of supercooling for excipient-free (Mb-A, panel A) and sucrose-containing (Mb-
B, panel B) myoglobin formulations lyophilized without controlled nucleation. Thermocouples were 
placed inside the vial in contact with the solution and also taped to the outside of the same vial. 
Mb-A showed supercooling to ~ -7.5 ± 0.4 °C and Mb-B showed supercooling to ~ -9.1 ± 0.4 °C as 
measured by thermocouples placed both inside and outside the vial. 
 
4.4.3 Solid-State Characterization by X-ray Diffraction and FTIR 
All the formulations were amorphous after freeze-drying and produced X-ray diffraction patterns 
consistent with amorphous materials (Appendix Fig. A9). Both Mb-A and Mb-B retained some 
degree of alpha helicity, observed as a peak at about 1652 cm-1 in the second-derivative FTIR 
spectra (Fig. 4.3). Mb-B with and without controlled nucleation showed a more intense and 
narrower alpha helix peak than excipient-free Mb-A formulations, although there was no 
appearance of beta sheet peaks in any of the spectra (Fig. 4.3). Overall, the two processes appear 







Figure 4.3. Second-derivative solid-state FTIR spectra for excipient-free (Mb-A) and sucrose-
containing (Mb-B) lyophilized myoglobin formulations. Spectra were obtained for Mb-A and Mb-B 
lyophilized with controlled nucleation (black and red curves respectively) and without controlled 
nucleation (blue and green curves respectively). 
 
4.4.4 Cake Morphology 
SEM images showed porous cakes for all formulations. Mb-A and Mb-B lyophilized with controlled 
nucleation showed more uniform pore structure than the formulations lyophilized without controlled 
nucleation (Fig. 4.4, Appendix Fig. A10). Mb-A lyophilized with and without controlled nucleation 
showed large plate-like morphology (Appendix Fig. A10, panels A, B) and Mb-B lyophilized with 
and without controlled nucleation showed thinner plates (Appendix Fig. A10, panels C, D). The data 
are consistent with the degree of supercooling (Fig. 4.1), since the formulations lyophilized with 
controlled nucleation showed a lower degree of supercooling and larger pores than those 






Figure 4.4. SEM images of excipient-free (Mb-A; panels A, B) and sucrose-containing (Mb-B; 
panels C, D) lyophilized myoglobin formulations. Panels A, C: Formulations lyophilized with 
controlled nucleation; Panels B, D: Formulations lyophilized without controlled nucleation. The top 
and bottom of each image represent the top and bottom of the cake respectively. Scale bars are 
set at 1 mm. 
 
4.4.5 Effects of Formulation and Process on Protein Backbone by ssHDX-MS 
Deuterated intact protein mass spectra showed an increase in mass compared to the undeuterated 
protein (Fig. 4.5). Since sorption and diffusion of D2O from the vapor phase into the solid must 
precede the hydrogen-deuterium exchange reaction in the solid state, the observed ssHDX rate 
can be affected by the rate and extent of sorption 30. To determine the effect of D2O sorption on 
ssHDX kinetics, moisture uptake was measured using TGA to simulate D2O uptake at 43 % 
humidity. Moisture sorption at 43 % RH was complete within 1 h for both Mb-A and Mb-B 
formulations, irrespective of the type of freezing (Appendix, Fig. A11). Since ssHDX continues over 
Mb-A












Figure 4.5. Deconvoluted mass spectra for excipient-free (Mb-A) and sucrose-containing (Mb-B) 
myoglobin formulations after 48 h of solid-state hydrogen-deuterium exchange at 5 °C, 43 % RH. 
Mass spectra were obtained for Mb-A and Mb-B lyophilized with controlled nucleation (blue and 
green curves respectively) and without controlled nucleation (red and orange curves respectively). 
The dashed curve represents the deconvoluted spectrum for undeuterated protein. 
 
ssHDX was relatively rapid in both Mb-A and Mb-B formulations lyophilized with or without 
controlled nucleation up to ~ 24 h and slowed at ~ 84 h for all samples (Fig. 4.6 A, B). At each time 
point, sucrose-containing formulations showed significantly lower deuterium uptake than the 
excipient-free formulations, suggesting greater backbone protection in the solid state. Deuterium 
uptake in the Mb-A formulation was not significantly different (p > 0.05) when the protein was frozen 
with or without controlled nucleation (Fig. 4.6A); similar results were observed for Mb-B with or 
without controlled nucleation (Fig. 4.6B). The initial moisture content after lyophilization (without 
incubation over water or D2O) of the formulations as measured by TGA were as follows: 2.9 % (Mb-
A, controlled nucleation), 4.0 % (Mb-A, uncontrolled nucleation), 3.4 % (Mb-B, controlled nucleation) 




moisture sorption at 43 % RH, differences in moisture sorption were observed between Mb-A and 
Mb-B formulations, but not between controlled and uncontrolled nucleation. Mb-A lyophilized with 
and without controlled nucleation sorbed ~ 0.12 and 0.13 g water/g dry solid respectively (~ 12.3 % 
and 12.7 % moisture respectively), and Mb-B lyophilized with and without controlled nucleation 
sorbed ~ 0.09 g water/g dry solid respectively (~ 9.4 % moisture for both; Appendix Fig. A11) within 
1 h of incubation. Hence the increased deuterium uptake for Mb-A may be related to the extent of 




Figure 4.6. (A) Deuterium uptake kinetics for excipient-free myoglobin (Mb-A) lyophilized with 
controlled nucleation (closed circles) and without controlled nucleation (open circles). (B) 
Deuterium uptake kinetics for myoglobin-sucrose formulation (Mb-B) lyophilized with controlled 




uptake kinetics for Mb-A (circles) and Mb-B (triangles) lyophilized with controlled nucleation. (D) 
Deuterium uptake kinetics for Mb-A (circles) and Mb-B (triangles) lyophilized without controlled 
nucleation. Each point represents the average number of deuterons (± SD) incorporated after 
incubation at 43 % RH, 5 °C for 0.5, 2, 6, 12, 24, 48, 84 and 120 h. 
 
Comparison of peak widths at similar deuterium uptake levels can provide information on the 
conformational and/or spatial heterogeneity of protein in different formulations. The sucrose 
formulation lyophilized with or without controlled nucleation showed significantly narrower peak 
widths (p < 0.05) than the excipient-free formulation at ~ 28 % deuteration  (Fig. 4.5, Table 4.2). 
Peak widths for Mb-B were about 26 % smaller than those for Mb-A formulations, irrespective of 
the type of freezing. No significant differences in peak widths were observed between controlled 
and uncontrolled nucleation within each formulation. 
 
Table 4.2. ssHDX-MS peak widths for myoglobin formulations in the absence (Mb-A) and presence 
(Mb-B) of sucrose lyophilized with or without controlled nucleation. Peak widths at ~28 % 
deuteration were calculated from the deconvoluted mass spectra for each formulation at 20 % peak 
height. 
Formulation 
Peak Width (Da) 
Controlled Nucleation Uncontrolled Nucleation 
Mb-A a 38.0 ± 1.0 38.3 ± 0.6 
Mb-B a 28.0 ± 0.0 27.7 ± 0.6 
a  Mb-A, myoglobin lyophilized without excipients; Mb-B, myoglobin lyophilized with sucrose 
 
4.4.6 Effects of Formulation and Process on Protein Side-Chain by ssPL-MS 
Up to 2 pLeu labels were detected for all formulations lyophilized with pLeu and irradiated with UV 
light (Fig. 4.7A). Mb-A lyophilized with and without controlled nucleation showed similar pLeu 




Mb-A with and without controlled nucleation respectively, as detected by LC-MS. Similar pLeu 
incorporation (7 ± 1 %) was observed for Mb-B without controlled nucleation. The greatest pLeu 
incorporation was detected for Mb-B with controlled nucleation (11 ± 1 %). Comparing Mb-A and 
Mb-B formulations lyophilized with controlled nucleation, the fraction of intact protein labeled 
increased significantly for Mb-B. There was no significant difference in the fraction of labeled protein 
in Mb-A and Mb-B formulations lyophilized without controlled nucleation. 
 
 
Figure 4.7. (A) Deconvoluted mass spectra for unlabeled myoglobin (dotted line) and myoglobin 
labeled with photo-leucine (solid line). The spectrum for labeled myoglobin has been offset 
vertically to show differences. Peaks corresponding to the mass of unlabeled (0 L, ~ 16951 Da) 
and protein with 1 label (1 L, ~ 17066 Da) were detected. A peak for myoglobin labeled with 2 labels 
(~ 17182 Da) was also detected, but not shown here since the intensity was low. Similar spectra 
with up to 2 labels were obtained for excipient-free (Mb-A) and sucrose-containing (Mb-B) 
myoglobin formulations lyophilized with and without controlled nucleation. (B) Fraction of protein 
labeled with photo-leucine for Mb-A and Mb-B formulations lyophilized with controlled nucleation 




labeled protein on the extracted ion chromatogram (EIC) obtained by LC-MS. The bars show the 
mean (± SD) of three LC-MS injections. The following pairs showed significantly different means (p 
< 0.05, GraphPad Prism) using one-way ANOVA: Mb-A CN vs. Mb-B CN and Mb-B CN vs. Mb-B 
UCN. 
 
At the peptide level, complete sequence coverage was obtained after tryptic digestion and LC-MS 
analysis. Since photolytic labeling is associated with some degree of variability due to promiscuity 
of the carbene reaction, matrix heterogeneity and ionization efficiencies of labeled and unlabeled 
peptides, only labeled peptides that were detected in at least 2 of triplicate LC-MS injections were 
considered. Mb-A lyophilized with controlled nucleation and Mb-A and Mb-B lyophilized without 
controlled nucleation were labeled at peptide His103-Lys118 (Fig. 4.8A). Mb-B lyophilized with 
controlled nucleation was labeled at peptides Leu32-Lys42 and His103-Lys118 (Fig. 4.8B). 
 
 
Figure 4.8. Peptide-level labeling with photo-leucine for (A) excipient-free (Mb-A) myoglobin 
lyophilized with controlled nucleation. (B) Sucrose-containing (Mb-B) myoglobin lyophilized with 
controlled nucleation. Labeled peptides Leu32-Lys42 and Tyr103-Lys118 are represented in blue and 
the heme group is shown in red. Mb-A and Mb-B lyophilized without controlled nucleation showed 







holomyoglobin was obtained from the Protein Data Bank (www.rcsb.org; PDB ID 1WLA) and 
PyMOL was used to generate labeled ribbon diagrams (PyMOL Molecular Graphics System, 
Version 1.4.1, Schrödinger, LLC). 
 
4.5 DISCUSSION 
During scale-up in an aseptic environment, vials are expected to supercool to a greater degree 
than in a laboratory environment where there are more particulates. This, combined with vial 
position effects and the stochastic nature of ice nucleation, produces heterogeneous nucleation 
temperatures and ice crystal sizes in the sterile environment, resulting in prolonged drying cycles. 
Controlled nucleation can help improve inter-vial and inter-batch homogeneity and reduce drying 
times. Lyophilization-induced structural changes may affect protein stability when a process is 
transferred from laboratory-scale to production, however, and these changes may not be detected 
using conventional, global methods such as ssFTIR and differential scanning calorimetry. Here, we 
report the use of high-resolution ssHDX-MS and ssPL-MS to detect conformational changes in 
lyophilized formulations with process and formulation differences. 
 
ssHDX-MS results indicate that deuterium incorporation was affected significantly by formulation, 
but not the freezing step (Figs. 4.5, 4.6). Deuterium incorporation in the excipient-free formulation 
(Mb-A) was greater than in the formulation containing sucrose (Mb-B), consistent with greater 
structural perturbation and/or a decrease in matrix interactions in Mb-A (Fig. 4.5). Deuterium 
incorporation in both the excipient-free formulation and the sucrose-containing formulation was 
relatively unaffected by the freezing step (Fig. 4.5, orange vs. green curves, blue vs. red curves). 
That the type of freezing (controlled vs. uncontrolled nucleation) does not affect deuterium 
incorporation for both Mb-A and Mb-B suggests that the process does not significantly alter protein 
structure in this study. These findings are supported by ssHDX-MS kinetics (Fig. 4.6) and are 




In analyzing deuterium uptake kinetics, the peak width provides a measure of protein structural 
heterogeneity resulting from the distribution of deuterated populations 34, 35. Small increases in 
mass due to deuteration may not be detected if the peaks are not sufficiently resolved. This can 
cause peak broadening, wherein multiple deuterated populations comprise a wider peak. Peak 
widths for the Mb-A formulation were significantly greater than for Mb-B for both processes, 
consistent with greater structural and/or spatial heterogeneity in Mb-A than in Mb-B (Table 4.2). 
Within Mb-A or Mb-B formulations, peak widths for samples from the two processes were not 
significantly different (Table 4.2), suggesting similar structural and/or spatial heterogeneity with 
controlled and uncontrolled nucleation. 
 
Like ssHDX-MS, ssPL-MS provides qualitative and quantitative information on proteins in the solid 
state. Since the mass of a pLeu label (~ 115 Da) is much greater than that of a deuterium label, 
mass spectrometric peaks for unlabeled and singly labeled protein can be resolved easily and peak 
broadening is not observed. Assuming uniform pLeu distribution in the matrix, the fraction of protein 
labeled by pLeu quantifies the fraction of protein with side-chain exposure to pLeu. The fraction of 
labeled protein and map of the labeled regions (Figs. 4.7B, 4.8) provide information on pLeu 
exposure at the side-chain level. In the presence of sucrose in the lyophilized matrix, it is expected 
that pLeu labeling efficiency will be somewhat diluted, resulting in decreased labeling compared to 
an excipient-free formulation. However, pLeu labeling was similar (uncontrolled nucleation) or 
greater (controlled nucleation) in the Mb-B formulation compared to Mb-A (Fig. 4.7). Within Mb-A 
formulations, the fraction of labeled protein was similar (Fig. 4.7) and within Mb-B formulations, the 
fraction of labeled protein was greater for controlled nucleation than for uncontrolled nucleation, 
consistent with greater interactions with the matrix. This suggests that while uncontrolled nucleation 
results in equivalent side-chain matrix exposure in the presence or absence of sucrose, controlled 





Intact- and peptide-level pLeu labeling data indicate that side-chain exposure to pLeu is different 
for Mb-B lyophilized with controlled nucleation than for the other formulations, suggesting more 
favorable contacts between the protein and pLeu (Figs. 4.7, 4.8). The reasons for the increased 
fraction of labeled protein in Mb-B with controlled nucleation are not clear, but may be related to 
the distribution of pLeu and protein in the formulation and/or changes in protein conformation. 
Inhomogeneity in the freeze-concentrated liquid after ice crystallization has been reported 
previously 36-38. Efficiency of UV light penetration may also affect protein labeling. Smaller fill 
volumes result in lower cake height and better labeling efficiency (Appendix Fig. A12). Hence, 
ssPL-MS may not be representative of protein structure across the entire cake. Moreover, the 
uniform and large pore structure for Mb-B lyophilized with controlled nucleation may permit more 
efficient irradiation and pLeu labeling. Labeling of sucrose by pLeu was not detected by LC-MS, 
but may also affect protein labeling. Previous ssPL-MS results in our lab showed greater protein 
labeling in the presence of sucrose compared to guanidine hydrochloride 31. It is difficult to 
distinguish the effect of excipients from the effect of protein conformation on the nature of solid-
state labeling observed, and stability studies are needed to correlate the fraction of labeled protein 
with structure retention and interpret the side-chain labeling results. 
 
Together, the results show that controlled nucleation did not significantly affect protein conformation 
in this study as determined by ssFTIR and ssHDX-MS (Figs. 4.5, 4.6, 4.7 and 4.8) and may offer 
the advantage of reduced drying time. A similar absence of structural changes has been reported 
for IgG lyophilized with and without controlled nucleation 26, although solution-state analytical 
methods were used. In this study, formulation effects were more dominant than process effects. 
Additional studies on the effects of controlled nucleation on protein structure are needed in order 
to extend these results to other proteins, using a variety of protein-excipient systems.  
 
There were several unexpected observations in this study that merit further investigation.  In 




for pressurization, nucleation did not take place at -5 °C.  Instead, nucleation proceeded in an 
uncontrolled manner.  Controlled nucleation at -5 °C did take place when a fill volume of 500 µL 
was used in combination with argon as the pressurization gas.  Further investigation is needed in 
order to understand the role of vial size, relative fill volume, and pressurization gas on the 
robustness of the nucleation process using rapid depressurization. Controlled nucleation by rapid 
depressurization is highly directional, always proceeding from the top of the fill volume downward.  
For very small fill volumes, the dynamics of this top-down process is quickly interrupted.  It would 
be useful to study the effect of relative fill volume on protein structure perturbation using controlled 
nucleation by rapid depressurization. Generally speaking, the vials containing thermocouples 
nucleate before the unmonitored vials.  That did not happen when monitoring uncontrolled 
nucleation in this study.  In fact, the vials containing thermocouples nucleated last.  This could have 
been a random occurrence, but it may be useful to further examine the influence of thermocouples 
on nucleation when using very small fill volumes. 
 
Previous ssHDX-MS studies in our lab have shown a correlation between deuterium incorporation 
in freshly lyophilized samples and aggregation during storage over a year, with greater stability for 
formulations showing lower deuterium incorporation 29. It is reasonable to expect a similar 
correlation for process-induced differences in ssHDX, though extended storage stability studies 
were not conducted here. Based on this previous report and the ssHDX-MS results for intact Mb 
presented here (Fig. 4.5), stability would be expected to decrease in the order: (Mb-B without 
controlled nucleation) = (Mb-B with controlled nucleation) > (Mb-A without controlled nucleation) = 
(Mb-A with controlled nucleation). A similar trend in structure retention was observed by ssFTIR, 
although the data are qualitative. To our knowledge, the relationship between ssPL-MS results and 






Two formulations of Mb (with or without sucrose) were lyophilized according to the same 
lyophilization cycle with or without controlled nucleation and the effects on Mb conformation in the 
lyophilized solids were assessed using ssFTIR, ssHDX-MS and ssPL-MS. Formulation effects were 
dominant, with formulations containing sucrose showing better retention of structure by all 
measures than formulations without sucrose. Samples lyophilized with controlled nucleation did not 
differ from those lyophilized without controlled nucleation by most measures of structure. ssPL-MS 
showed greater pLeu incorporation and the involvement of more regions of the Mb molecule in Mb 
lyophilized with controlled nucleation in the presence of sucrose than for other conditions. The data 
support the use of ssHDX-MS and ssPL-MS to study formulation and process-induced 
conformational changes in lyophilized proteins.  
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CHAPTER 5. CONCLUSIONS 
This dissertation has described novel, high-resolution techniques to probe protein structure and 
environment in the solid state. These techniques are orthogonal to conventional analytical methods 
such as FTIR and Raman spectroscopy and provide peptide- to amino acid-level information about 
changes in protein structure and microenvironment in the solid state. 
 
The research presented in Chapter 2 shows the potential of solid-state photolytic labeling- mass 
spectrometry (ssPL-MS) to study protein structure with high resolution. Although labeling 
approaches have been described in solution, these have not been applied to the solid state 
previously, to the authors’ knowledge. Solid-state labeling overcomes the low resolution of methods 
such as Fourier-transform infrared (FTIR) spectroscopy and allows direct visualization of side-chain 
matrix accessibility. It does not depend on pH and can label the entire protein surface. 
 
ssPL-MS can be used to study storage stability in lyophilized formulations by measuring the change 
in side-chain accessibility. For example, vials containing lyophilized protein formulation with pLeu 
in the matrix can be stored at high temperature and/or humidity for accelerated stability studies. 
Samples can be withdrawn at definite intervals, irradiated and analyzed by LC-MS at the intact 
protein- and peptide level. Side-chain accessibility of peptides can be quantified using relative peak 
heights of unlabeled and labeled peptides obtained by LC-MS. This metric can be correlated with % 
monomeric protein observed by size exclusion chromatography. ssPL-MS can also be used to 
study the mechanism of solid-state aggregation by labeling protein formulations over the time 






The crosslinking approach described in Chapter 3 advances the labeling technique by allowing the 
protein structure as well as environment to be probed. Thus far, the effect of excipients on 
lyophilized protein structure has only been probed indirectly, based on FTIR band areas 1, 2. 
However, it is not clearly understood how the mechanism of protein stabilization changes when a 
protein in solution is lyophilized. To the authors’ knowledge, this is the first report of direct 
visualization of protein-matrix interactions in the solid state. The microenvironment around the 
protein could be examined with 3.9 Å resolution, comparable to X-ray crystallography resolution 
but without the need for large amounts of protein, isotopic labeling or crystallinity requirements.  
 
The effects of the excipients’ physical form on protein local structure were also observed using 
photolytic crosslinking. It is generally accepted that a stabilizing excipient must be in an amorphous 
state with the protein to allow better mixing and physical contact. Hence, excipients that remain 
amorphous during lyophilization, such as sucrose and trehalose, are expected to stabilize the 
protein to a greater degree than crystallizing excipients such as sodium chloride and mannitol. As 
described in Chapter 2, the microenvironment around the protein changed significantly when it was 
lyophilized, as observed by changes in the crosslinked adducts observed by LC-MS. Although 
guanidine hydrochloride (Gdn HCl) was in intimate contact with the protein in solution and caused 
protein unfolding, the excipient appeared to crystallize during lyophilization and produced different 
crosslinking patterns compared to solution. The raffinose formulation was expected to be more 
stable since carbohydrates such as sucrose and trehalose tend to remain in an amorphous phase 
with the protein during lyophilization 3. Although crystallinity was not detected by X-ray diffraction, 
the crosslinking patterns indicated possible micro-phase separation in the solid state. Such phase 
separating, albeit non-crystallizing, excipients may not provide adequate stabilization during 
lyophilization and/or storage. 
 
This research can be applied to other amorphous protein systems spanning a range of secondary 





Concentrations of disaccharides in the formulations can also be varied to study their effect on 
crosslinking patterns. Crosslinking data obtained from different protein and excipient systems can 
help build a model to describe and predict protein stability in the solid state. Furthermore, this 
method has the potential to provide insight into the mechanisms of protein stabilization by 
excipients, both in solution and solid state. Thus protein crosslinking can aid rational design of 
formulations. 
 
The Food and Drug Administration’s (FDA) emphasis on Quality by Design recognizes the need to 
improve product quality and reduce the risk of failure. This requires better analytical and predictive 
tools to identify process- and product-related variables and ultimately control them, thereby creating 
a Design Space. The results described in Chapter 4 showed that controlled ice nucleation did not 
affect local protein conformation significantly and that process- and excipient-related effects on 
protein local structure in the solid state can be monitored using high-resolution solid-state 
hydrogen-deuterium exchange-mass spectrometry (ssHDX) and solid-state photolytic labeling- 
mass spectrometry (ssPL-MS). The results highlight the potential of these analytical methods as 
QbD tools to provide predictive measures of protein stability. 
 
Gaps still exist in our knowledge of process effects on protein structure and function. While it is of 
interest to make the lyophilization process more efficient, the consequences of process-related 
stresses on protein stability must be evaluated during manufacture as well as storage. Proteins that 
are sensitive to lyophilization-induced structural changes such as lactate dehydrogenase and 
human growth hormone can be used as model proteins. ssHDX-MS, ssPL-MS and ssPC-MS can 
be used to study protein conformation changes as a function of lyophilization cycle parameters 
such as freezing and drying temperatures and times and chamber pressure. The effect of protein 
concentration, fill volume, type of excipient, vial shape and material must also be investigated. 
Storage stability studies at different temperatures and relative humidity can be performed with 





exchangeable amides, number of pLeu labels and number of protein-matrix adducts to describe 
product stability (using % monomer determined by size exclusion chromatography) must be 
evaluated. Thus, high-resolution methods for backbone and side-chain conformational change in 
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Figure A1. Digest map of native apoMb digested with a combination of trypsin and chymotrypsin. 
A total of 36 peptides were produced, of which the 13 shown by the shaded bars were selected to 
provide 100% sequence coverage. 
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Table A1. Theoretical and observed b- and y-ions from MS/MS analysis of native and labeled L32-
K42 in apoMb labeled with pLeu in lyophilized solids.  
 
I. Product ions with z=+1 produced by fragmenting native L32-K42 (m/z = 424.5609; z=+3) 








L b1 114.0919  y11 1271.6636  
F b2 261.1604 261.1586 y10 1158.5796  
T b3 362.2080 362.2050 y9 1011.5111 1011.5070 
G b4 419.2295 419.2223 y8 910.4635 910.4603 
H b5 556.2884 556.2834 y7 853.442 853.4381 
P b6 653.3412  y6 716.3831 716.3800 
E b7 782.3838 782.3758 y5 619.3303 619.3267 
T b8 883.4314 883.4253 y4 490.2877 490.2852 
L b9 996.5155  y3 389.2401 389.2385 
E b10 1125.5581  y2 276.1560 276.1544 










II. Product ions with z=+2 produced by fragmenting native L32-K42 (m/z = 424.5609; z=+3) 




L y11 636.3357 636.3344 
F y10 579.7937 579.7910 
T y9 506.2595 506.2572 
G y8 455.7357 455.7332 
H y7 427.2249 427.2230 
P y6 358.6955 358.6935 
E y5 310.1691  
T y4 245.6478  
L y3 195.1240  
E y2 138.5819  









III. Product ions with z=+2 produced by fragmenting labeled L32-K42 (m/z = 462.9133; z=+3) 












Mass difference (u)d 
M = Mlabeled – Munlabeled 
L y11 693.8674 693.8649   
F y10 637.3254 637.3184 579.789 115.0588 
T y9 563.7912 563.7873 506.2524 115.0698 
G y8 513.2673 513.2592 455.7365 115.0454 
H y7 484.7566 484.7525 427.2245 115.0560 
P y6 416.2271 416.2189 358.6996 115.0386 
E y5 367.7008    
T y4 303.1795    
L y3 252.6556    
E y2 196.1136    














IV. Product ions with z=+1 produced by fragmenting labeled L32-K42 (m/z = 462.9133; z=+3) 
 













M = Mlabeled – 
Munlabeled 
L y11 1386.7269    
F y10 1273.6429    
T y9 1126.5744    
G y8 1025.5268    
H y7 968.5053    
P y6 831.4464 831.4462 716.3819 115.0643 
E y5 734.3936 734.3989 619.3205 115.0784 
T y4 605.3510 605.3535 490.289 115.0645 
L y3 504.3034  389.2466  
E y2 391.2193  276.1541  
K   y1 262.1767  147.1118  
a Calculated m/z values. 
b m/z values obtained experimentally using mass spectrometry. 
c No b-ions were detected by MS for z = +2. 
d Mass difference M was calculated from m/z values in columns (B) and (C), using the formula M 







Table A2. Theoretical and observed b- and y-ions from MS/MS analysis of GCG (1-8)* dimer 
from formulation containing peptide lyophilized with L-leu. F* denotes p-benzoyl-L-
phenylalanine (pBpA). Calculated m/z values are denoted as ‘Theoretical m/z’ while m/z values 
obtained experimentally using mass spectrometry are denoted as ‘Observed m/z’. 
 
I. Internal fragment (non-cross-linked) product ions with z=+1 produced by fragmenting GCG (1-











H b1 138.0668 138.0656 y8 968.4110  
S b2 225.0988 225.0973 y7 831.3521  
Q b3 353.1574 353.1502 y6 744.3201  
G b4 410.1789  y5 616.2615  
T b5 511.2265 511.2234 y4 559.2400 559.2367 
F*a b6 762.3207  y3 458.1923 458.1916 
T b7 863.3684  y2 207.0981 207.0963 









II. Cross-linked product ions with z=+2 produced by fragmenting GCG (1-8)* dimer (m/z = 
646.2783; z=+3) 










H b1 553.2400  y8 968.9173 968.9178 
S b2 596.7560  y7 890.8773  
Q b3 660.7853  y6 847.3613 847.3526 
G b4 689.2960 689.2939 y5 783.3320 783.3290 
T b5 739.8198 739.8130 y4 754.8213  
F* b6 865.3669 865.3627 y3 704.2975  
T b7 915.8908 915.8929 y2 578.7504  
S b8 959.4068  y1 528.2265   
a F* = p-benzoyl-L-phenylalanine (pBpA). 
b Calculated m/z values. 
c m/z values obtained experimentally using mass spectrometry. 
d α = GCG (1-8)* monomer. 
 
 
Table A3. List of SDA-labeled tryptic peptides selected for LC-MS/MS analysis. 
(Gly1-Lys16) L1 a (His48-Lys56) L1 
(Leu32-Lys45) L1 (Lys79-Lys96) L1 
(Leu32-Lys47) L1 (His97-Lys118) L1 
(Phe43-Lys56) L4 a (Tyr146-Gly153) L1 
(Phe46-Lys50) L2 a  




















Figure A2. Mechanism of crosslinking using succinimidyl 4,4’- azipentanoate (NHS-diazirine; SDA). 
In the first step (A), the protein is incubated with SDA which results in derivatization of primary 
amine containing side-chains. In the second step (B), the SDA-labeled protein is exposed to UV 
light (365 nm) and forms a reactive carbene intermediate with the loss of N2. The carbene forms 
covalent adducts with reactants (R) within the distance of the spacer arm (R = water, formulation 















Figure A3. Comparison of (A) photolabeling and (B) photocrosslinking methods. In photolabeling, 
the protein is exposed to UV irradiation (365nm) in the presence of a photoactive reagent in the 
excipient matrix. In photocrosslinking, a protein derivatized with a bifunctional photoactive reagent 
is exposed to UV light (365 nm) in the presence of other matrix components (e.g. water, formulation 













Figure A4. Second derivative amide I FTIR spectra of Mb-SDA (solid line) and unlabeled Mb 
(dashed line) Mb in formulations (A) Mb alone (control), (B) Mb with raffinose and (C) Mb with Gdn 
HCl. The band intensity (1650-1655 cm-1) observed for A and B indicates the presence of α-helix 












































Table A4. List of all possible peptide-water adducts that can be formed by crosslinking with SDA. 
A maximum of 4 SDA labels per peptide (and hence up to 4 H2O and 4 raffinose molecules per 
peptide) were considered. The same list was considered for all possible peptide-raffinose adducts. 
Peptide + 1SDA – 1N2 
+ 1H2O 
Peptide + 2SDA – 1N2 
+ 1H2O 
Peptide + 3SDA – 1N2 
+ 1H2O 
Peptide + 4SDA – 
1N2 + 1H2O 
 
Peptide + 2SDA – 2N2 
+ 1H2O 
Peptide + 3SDA – 2N2 
+ 1H2O 
Peptide + 4SDA – 
2N2 + 1H2O 
 
Peptide + 1SDA – 2N2 
+ 2H2O 
Peptide + 3SDA – 2N2 
+ 2H2O 
Peptide + 4SDA – 
2N2 + 2H2O 
  
Peptide + 3SDA – 3N2 
+ 1H2O 
Peptide + 4SDA – 
3N2 + 1H2O 
  
Peptide + 3SDA – 3N2 
+ 2H2O 
Peptide + 4SDA – 
3N2 + 2H2O 
  
Peptide + 3SDA – 3N2 
+ 3H2O 
Peptide + 4SDA – 
3N2 + 3H2O 
   
Peptide + 4SDA – 
4N2 + 1H2O 
   
Peptide + 4SDA – 
4N2 + 2H2O 
   
Peptide + 4SDA – 
4N2 + 3H2O 
   
Peptide + 4SDA – 
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Figure A5. Peptide-peptide adducts formed in (A) Mb-SDA alone (control), (B) Mb-SDA with 
raffinose and (C) Mb-SDA with Gdn HCl lyophilized formulations. Peptide-peptide adducts formed 
by maximum one (■), two (■), three (■) and four (■) SDA molecules from a single sample injection 
are plotted. The -helices from N-terminus to C-terminus in Mb are represented by cylinders 
labeled A to H respectively. 
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Figure A6. Tryptic peptides of Mb detected as peptide-water adducts in (A) Mb-SDA alone (control), 
(B) Mb-SDA with raffinose, (C) Mb-SDA with Gdn HCl lyophilized formulations and (D) Tryptic 
peptides of Mb detected as peptide-raffinose adducts in Mb-SDA with lyophilized raffinose 
formulation. Peptide-water adducts formed by maximum one (■), two (■), three (■) and four (■) 





with maximum one molecule of raffinose are plotted in orange. The α-helices from N-terminus to 
C-terminus in Mb are represented by cylinders labeled A to H respectively. 
* The molecular mass of tryptic fragments 63-77 and 64-78; 63-78 and 64-79 are identical and 
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Figure A7. Peptide-peptide adducts formed in (A) Mb-SDA control, (B) Mb-SDA with raffinose and 
(C) Mb-SDA with Gdn HCl solution formulations. Peptide-peptide adducts detected in single (■), 
duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped irrespective 
of the number of SDA linkages (1-4 SDA). The -helices from N-terminus to C-terminus in Mb are 
represented by cylinders labeled A to H respectively. * The molecular mass of tryptic fragments 63-
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peptide-peptide adducts (32-45 x 43-47) and (32-47 x 43-45); (79-87 x 51-63) and (78-87 x 51-62); 






































Figure A8. Percent weight loss with time at 50 ˚C, 0 % RH for Mb-SDA alone (dotted line), Mb-



























Figure A9. X-ray diffractograms of lyophilized excipient-free (Mb-A) and sucrose-containing (Mb-
B) myoglobin formulations. Crystalline features were not observed for Mb-A lyophilized with (black 
line) and without (blue line) controlled nucleation. Similar diffractograms were obtained for Mb-B 







Figure A10. SEM images of excipient-free (Mb-A; panels A, B) and sucrose-containing (Mb-B; 
panels C, D) lyophilized myoglobin formulations. Panels A, C: Formulations lyophilized with 
controlled nucleation; Panels B, D: Formulations lyophilized without controlled nucleation. The top 
and bottom of each image represents the top and bottom of the cake respectively. Scale bars are 
set at 500 µm. 
  
Mb-A










Figure A11. Moisture sorption kinetics for excipient-free (Mb-A) myoglobin formulations lyophilized 
with (black line) and without (blue line) controlled nucleation and sucrose-containing (Mb-B) 
myoglobin formulations lyophilized with (red line) and without (green line) controlled nucleation. 







Figure A12. Fraction of protein labeled with photo-leucine for excipient-free (Mb-A) and sucrose-
containing (Mb-B) myoglobin formulations lyophilized without controlled nucleation with a fill volume 
of 200 or 500 µL. All lyophilized formulations contained 100:1 molar ratio of pLeu to protein and 
were irradiated for 40 min at 365 nm. The fraction was calculated using peak heights of labeled 
protein on the extracted ion chromatogram (EIC) obtained by LC-MS. The bars show the mean (± 
SD) of three LC-MS injections. The two fill volumes showed significantly different means using a 
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